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ABSTRACT 
 
Investigation of the interactions of Retinoblastoma Binding Protein-6 
with transcription factors p53 and Y-Box Binding Protein-1 
 
A. Faro, PhD (Biotechnology) thesis, Department of Biotechnology, Faculty of 
Natural Sciences, University of the Western Cape 
 
Retinoblastoma Binding Protein 6 (RBBP6) is a 250 kDa multi-domain protein that 
has been implicated in diverse cellular processes including apoptosis, mRNA 
processing and cell cycle regulation. Many of these functions are likely to be related 
to its interaction with tumour suppressor proteins p53 and the Retinoblastoma 
protein (pRb), and the oncogenic Y-Box Binding Protein-1 (YB-1). RBBP6 inhibits the 
binding of p53 to DNA and enhances the HDM2-mediated ubiquitination and 
proteasomal degradation of p53. Disruption of RBBP6 leads to an embryonic lethal 
phenotype in mice as a result of widespread p53-mediated apoptosis. RBBP6 
promotes ubiquitination and degradation of YB-1, leading to its proteasomal 
degradation in vivo.  
 
The first part of this thesis describes in vitro investigations of the interaction between 
bacterially-expressed human p53 and fragments of human RBBP6 previously 
identified as interacting with p53, in an attempt to further localise the region of 
interaction on both proteins. GST-pull down assays and immunoprecipitation assays 
confirmed the interaction, and localised it to the core DNA binding domain of p53 and 
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a region corresponding to residues 1422-1668 of RBBP6. However in Nuclear 
Magnetic Resonance (NMR) chemical shift perturbation assays no evidence was 
found for the interaction. NMR showed the relevant region of RBBP6 to be unfolded, 
and no evidence was found for interaction-induced folding. The R273H mutant of the 
p53 core domain did not abolish the interaction, in contrast to reports that the 
corresponding murine mutation (R270C) did abolish the interaction. 
 
The second part of this thesis describes in vitro investigations of the ubiquitination of 
YB-1 by RBBP6. A fragment corresponding to the first 335 residues of RBBP6, 
denoted R3, was expressed in bacteria and found to be soluble. Contrary to 
expectation, in a fully in vitro assay R3 was not able to ubiquitinate YB-1. However, 
following addition of human cell lysate, YB-1 was degraded in an R3-dependent and 
proteasome-dependent manner, indicating that R3 is required for ubiquitination and 
proteasomal degradation of YB-1. However R3 is not sufficient, with one or more 
factors being supplied by the cell lysate. In view of the pro-tumourigenic effects of 
YB-1 in many human cancers, these results lay the foundation for an understanding 
of the regulatory effect of RBBP6 on YB-1 and its potential role in anti-tumour 
therapy. 
 
Keywords: RBBP6, p53, YB-1, tumour suppressor, cancer, ubiquitination, E3 ligase, 
immunoprecipitation, NMR, protein 
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Chapter 1: Literature review 
1.1 Introduction 
Retinoblastoma binding protein 6 (RBBP6) is a multi-functional protein found in all 
eukaryotes. The protein directly interacts with the tumour suppressor proteins p53 
and pRb and has been implicated in mRNA processing, apoptosis, embryonic 
development and cell cycle control. The protein contains a number of conserved 
domains, including an N-terminal ubiquitin-like domain, a zinc finger domain and 
RING finger domain. Through its RING finger domain RBBP6 has been shown to 
promote the MDM2-mediated ubiquitination and proteasomal degradation of p53. 
Also through its RING finger domain RBBP6 promotes the degradation of the pro-
proliferative transcription factor Y-box Binding Protein 1 (YB-1). 
 
The structure of the RING finger of RBBP6, which has recently been determined, 
suggests that the domain has characteristics of both a RING finger and a U-box 
domain. U-box-containing proteins, such as the C-terminus of Hsp70 Interacting 
Protein (CHIP), cooperate with chaperones such as Hsp70 and Hsp90 to target 
unfolded proteins for ubiquitination and proteasomal degradation, thus functioning in 
protein quality control. The N-terminal ubiquitin-like domain of RBBP6, denoted 
DWNN, has recently been shown to interact with the chaperones Hsp70 and Hsp40, 
suggesting that RBBP6 may also participate in chaperone-mediated protein quality 
control. 
 
P53 is a master regulator of diverse cellular processes, including cell cycle 
regulation, DNA damage repair and apoptosis, while up-regulation of YB-1 
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expression is associated with resistance to chemotherapy during cancer treatment, 
making it an attractive target for therapeutics aimed at fighting tumourigenesis. This 
study aimed to characterise the interactions of RBBP6 with both p53 and YB-1 in 
vitro with the view of gaining further insight into the mechanisms underlying 
regulation of these proteins.  
 
1.2 Retinoblastoma binding protein 6 (RBBP6) 
Retinoblastoma binding protein 6 is a 250 kDa multi-domain nuclear protein, which 
has been implicated in mRNA processing, cell cycle control and apoptosis. It 
interacts with the tumour suppressor proteins pRb and p53 and has been implicated 
in regulating ubiquitination of p53 by MDM2 [6-8]. At least 3 major transcripts are 
produced from the RBBP6 gene, by a combination of alternative splicing and 
alternative polyadenylation in humans. These transcripts encode proteins of 1792, 
1758 and 118 amino acids, which have been designated isoforms 1, 2 and 3 
(Genbank: NP_008841, Genbank: NP_061173, Genbank: NP_116015).  
 
The domain organisation of RBBP6 proteins from different eukaryotic organisms is 
shown in Figure 1.1. The gene is found as a single copy in all eukaryotic genomes 
analysed to date. All RBBP6 homologues have an N-terminal ubiquitin-like domain, 
called the DWNN domain, followed by a CCHC zinc finger and a RING finger. In 
higher eukaryotes the protein contains additional domains including a proline rich 
domain (residues 337–349), an SR domain (residues 679–773), as well as the pRb 
(residues 964-1120) and p53 binding domains (residues 1142-1727) [1]. In humans 
the DWNN domain is also independently expressed as a 13 kDa protein consisting 
of the DWNN domain and a long, unstructured C-terminal tail (isoform 3).  
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Figure 1.1 Domain organisation of RBBP6 proteins All RBBP6 homologues have an 
N-terminal ubiquitin-like domain, called the DWNN domain, followed by a CCHC zinc 
finger and a RING finger. Human RBBP6 isoform 1 has additional domains, including a 
proline rich domain (residues 337–349), SR domain (residues 679–773), as well as the 
pRb (964-1120) and p53 binding domains (residues 1142-1727). Human RBBP6 is also 
expressed as a 13 kDa protein containing only the DWNN domain, with a long C-terminal 
tail. Figure adapted from Pugh et al [1]. 
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In addition to these domains, the C-terminus of RBBP6 contains extensive regions 
with no recognisable homology that are predicted to be intrinsically disordered.  
 
RBBP6 was originally isolated and cloned in three independent studies published in 
1995 and 1997. Sakai and co-workers screened a small lung cell carcinoma 
expression library to probe for pRb interacting partners and identified a 140 kDa 
protein that binds to hypophosphorylated pRb, which they named RBQ-1 [6]. RBQ-1 
corresponds to residues 150–1146 of human RBBP6. RBQ-1 binding to pRb was 
inhibited by adenovirus E1A protein, suggesting that RBQ-1 binds to the pRb pocket 
domain and that the binding is therefore physiologically relevant. A region of 34 
amino acids in the middle of the RBQ-1 sequence was found to be alternatively 
spliced.  
 
Using a similar approach, but with p53 as probe, Simons and co-workers identified a 
mouse homologue of RBQ-1 which they named PACT, for p53 Associated Cellular 
protein-Testes derived (GenBank: AAL68925.1) [7]. Subsequent analysis of the 
cDNA sequences revealed that RBQ-1 is a truncated form of PACT. PACT is itself a 
truncated form of RBBP6 spanning residues 207-1792 of human RBBP6, excluding 
only the DWNN domain. PACT could bind to wild type p53 but not to mutant forms of 
p53 that are deficient in DNA-binding, such as R270C (mouse). PACT binding to p53 
could inhibit the sequence-specific DNA binding of p53. The authors also 
demonstrated that PACT could simultaneously bind p53 and pRb by showing that 
the three proteins co-precipitate in immune complexes.  
 
Independently, Witte and Scott identified a murine protein they called Proliferation  
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Potential Related protein (P2P-R) (Genbank: AAL05625.1), based on its association 
with heterogeneous nuclear ribonucleoprotein particles [9]. P2P-R corresponds to 
residues 199-1792 of human RBBP6 and is therefore almost identical to PACT, 
which is also a murine protein. Witte and Scott showed that P2P-R expression is 
markedly repressed during terminal differentiation. Overexpression of near full-length 
P2P-R restricts mitotic progression at prometaphase and promotes mitotic apoptosis 
in Saos2 (Sarcoma osteogenic 2) cells [9]. In apoptotic cells, P2P-R localisation 
changes from a predominantly nuclear distribution to the cytoplasm and cell surface 
blebs. At the same time, the immunoreactivity of the protein appears to increase 
significantly. Saos2 cells lack p53 because of a deletion in the p53 coding region and 
also have a non-functional pRb, leading Gao and Scott to conclude that the effects of 
P2P-R overexpression are independent of these two tumour suppressors. Instead 
they speculated that P2P-R-induced apoptosis involves a caspase-3 dependent 
pathway. Caspase-3 is an effector caspase, cleaving many cellular proteins including 
pRb, MDM2 and topoisomerase I, in response to apoptotic stimuli [10]. 
 
PACT may function as part of the cellular pre-mRNA splicing machinery, based on 
its localisation to nuclear speckles, the main site of pre-mRNA processing and the 
presence of a serine/arginine (SR) rich region similar to that found in members of the 
SR family of splicing factors [7]. Further evidence for the involvement of RBBP6 in 
RNA processing came from the study by Witte and Scott which showed that RBBP6 
associates with heterogeneous nuclear ribonucleoprotein particles and could bind 
single stranded nucleic acids [11]. During interphase P2P-R localises primarily to 
nucleoli, the site of mRNA processing. In 2001, Vo and co-workers reported that 
Mpe1p, the yeast homolog of RBBP6, is an essential subunit of the Saccharomyces 
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cerevisiae Cleavage and Polyadenylation Factor and that Mpe1p is required for 
mRNA 3’-end cleavage and polyadenylation [12]. Recently, the complete human pre-
mRNA 3’ processing complex and showed using mass spectrometry that RBBP6 
forms part of the complex [13]. Despite the accumulation of evidence for the 
involvement of RBBP6 in mRNA processing, its precise role is still far from being 
understood. 
 
RBBP6 expression is strongly up-regulated in oesophageal cancer, correlating with 
higher rates of proliferation of cultured oesophageal cancer cells and lower survival 
rates in cancer patients [14]. Cytotoxic T cells specific for RBBP6-derived peptides 
were able to lyse cultured oesophageal cancer cells and regress oesophageal 
tumours in mouse xenograft models, identifying RBBP6 as a potential candidate for 
immunotherapy against oesophageal cancer.  
 
Li and co-workers demonstrated that the RBBP6/p53 interaction might be anti-
apoptotic, at least during embryonic development [8]. The authors generated RBBP6 
knock-out mice by replacing the p53 binding domain with a neomycin gene in 
embryonic stem cells. The targeted embryonic stem cells were used to generate 
chimeric mice which were crossed with wild-type mice. The RBBP6-/- phenotype is 
lethal, with embryos dying before E7.5 as a result of p53 accumulation and 
increased apoptosis. The lethal phenotype was partially rescued by a p53-null 
background, with embryos surviving longer. The results from this study suggested 
that RBBP6 plays an essential role in embryonic development, possibly as a 
consequence of its interaction with p53. These results are in agreement with an 
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earlier report by Mather and co-workers that RBBP6 is essential for embryonic 
development in Drosophila melanogaster [15].  
 
Li and co-workers also demonstrated that RBBP6 interacts directly with HDM2 and 
promotes the ubiquitination and degradation of p53. While overexpression of RBBP6 
in HEK293 cells had no effect on p53 ubiquitination, co-transfection of RBBP6 and 
HDM2 led to enhanced ubiquitination and degradation of p53. Replacement of 
RBBP6 by a mutant lacking the RING finger abolished the enhancement of p53 
degradation. It was furthermore shown by co-transfection of a p53-responsive 
reporter plasmid and increasing amounts of RBBP6 that RBBP6 inhibited the 
transcriptional activity of p53 in a dose-dependent manner, while inactivation of 
RBBP6 stabilized p53 and induced p53-dependent apoptosis. The results from this 
study establish RBBP6 as a negative regulator of p53 and shows that RBBP6 is 
essential for early embryonic development. The authors suggested that RBBP6 may 
function as a scaffold for the assembly of the p53-HMD2 complex [8]. 
 
1.1 The p53 tumour suppressor 
“Guardian of the genome”, “Policeman of the oncogenes”, “Dictator of life and death” 
are all names attributed to the tumour suppressor protein p53. They highlight the 
central role that p53 plays in cell cycle control, DNA repair and apoptosis. The 
importance of p53 in normal cellular homeostasis is illustrated by the fact that of the 
order of 50 % of all human cancers results from mutations in the p53 gene. The 
majority of these mutations occur in the core DNA binding domain of p53 [16, 17].  
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p53 domain organisation and function 
The p53 gene is located on the short arm of chromosome 17 and codes for a 53 kDa 
protein, hence the name p53. Figure 1.2, adapted from Joerger and Fersht, depicts 
the domain organisation of p53 and the location of known mutations [18]. Human 
p53 has 393 residues and consists of an intrinsically unfolded N-terminal 
transactivation domain (residues 1-61), a proline rich region (residues 64-92), the 
central DNA binding domain (residues 94-292), a tetramerization domain (residues 
325-356) and the C-terminal regulatory domain (residues 363-393). The N-terminal 
transactivation domain (TAD) is responsible for transcriptional activation and is also 
the main site of interaction for proteins that control the transcriptional activity of p53, 
such as components of the transcription machinery, MDM2, MDMX and p300/CBP. 
The exact role of the proline rich region is unclear, but it may serve as a linker 
between functional domains; Wells and co-workers found that the proline rich region 
tends to adopt a stiff polyproline II (PPII) structure that orients the TAD away from 
the central core domain [19]. The core domain is responsible for sequence-specific 
DNA binding, while the tetramerization domain mediates the oligomerization state of 
p53. Full-length active p53 binds DNA as a tetramer of approximately 210 kDa. The 
C-terminal regulatory domain undergoes extensive post-translational modifications 
that regulate p53 function, including ubiquitination, sumoylation, neddylation, 
phosphorylation and acetylation. Acetylation of C-terminal lysines modulates the 
transcriptional activity of p53 by enhancing sequence-specific binding to DNA [20]. 
Ubiquitination on the C-terminus by MDM2 is the primary mechanism for down-
regulation of p53 by proteolysis in the 26S proteasome [21].     
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Figure 1.2 Domain structure of p53 and position and relative frequency of 
some p53 mutations Human p53 consists of an N-terminal transactivation 
domain (residues 1-61), a proline rich region (residues 64-92), a central DNA 
binding domain (residues 94-292), a tetramerization domain (residues 325-356) 
and the C-terminal regulatory domain (residues 363-393). The diagram indicates 
that most p53 mutations map to the central DNA binding domain. Figure adapted 
from Joerger and Fersht [17]. 
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Cell cycle arrest and apoptosis are the most frequent cellular responses activated by 
p53. In response to DNA damage, p53 induces the expression of the cyclin 
dependent kinase (CDK) inhibitor p21WAF1, which restricts cell cycle progression at 
the G1-S transition [22]. P21WAF1 is a member of the Cip/Kip family of CDK 
inhibitors, whose members inhibit a range of CDKs including cdk2, cdk4 and cdk6. In 
addition to its ability to inhibit CDKs, p21WAF1 also binds to and inhibits the DNA 
replication factor PCNA (proliferating cell nuclear antigen), an auxiliary protein to 
DNA polymerase-δ which is required for DNA synthesis. As part of the response to 
γ-radiation-induced DNA damage, p53 induces the expression of 14-3-3-σ which 
sequesters cdk2 in the cytoplasm, thereby contributing to G2 arrest [23]. In addition 
to inhibiting cdk2, 14-3-3-σ enhances p53 stability by blocking MDM2-mediated 
nuclear export of p53, thereby preventing the cytoplasmic degradation of p53 by the 
proteasome. 14-3-3-σ also facilitates p53 dimer-dimer interactions, thereby 
stabilising p53 DNA binding and promoting p53 transcriptional activity.  
 
P53 functions primarily as a transcription factor, activating or repressing a host of 
downstream genes by binding to responsive elements within their promoter regions. 
The p53 consensus sequence consists of either a 10-base pair repeat of 5’-PuPuPu-
C(A/T)(T/A)GPyPyPy-3’ separated by 0–13 base pairs (where Pu is a purine and Py 
is a pyrimidine) or a palindromic site comprised of four 5-base pair inverted repeats 
with a similar sequence [24]. 
 
Many p53 transcriptional targets trigger an apoptotic response, including the pro-
apoptotic Bcl-2 family members Puma, Noxa, Bax and Bid, which are members of 
the intrinsic apoptosis pathway; also APAF-1 (apoptotic protease activating factor-1), 
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Fas/CD95, death receptor 4 (DR4) and DR5, which are members of the extrinsic 
pathway. There is also evidence that p53 can trigger apoptosis directly by binding to 
and inhibiting the anti-apoptotic proteins Bcl-x(L) and Bcl-2, leading to mitochondrial 
permeabilization and the release of cytochrome c and SMAC [25], which in turn 
leads to caspase activation and apoptosis. Figure 1.3, which is adapted from 
Michalak and co-workers summarises the cellular response to p53 activation [3]. 
 
Regulation of p53 
The regulation of p53 is very complex, involving diverse post-translational 
modifications including phosphorylation, acetylation, methylation, sumoylation and 
ubiquitination. The cellular levels of p53 are normally low (p53 has a half-life of 5 to 
30 minutes) but stress signals can induce its stabilisation and activation. The normal 
cellular levels of p53 are primarily regulated by MDM2, an E3 ubiquitin ligase which 
targets it to the proteasome [26-29]. The importance of MDM2 in the regulation of 
p53 is highlighted by the fact that 5-10 % of all human tumours show excess MDM2 
expression, resulting in increased silencing of p53, thus removing the tumour 
suppressor function of p53. Overexpression of MDM2 enables human fibroblasts 
expressing E1A and activated Ras to develop tumours in nude mice [30].  
 
MDM2 regulates p53 activity in at least three ways: by blocking its transactivational 
activity, by catalysing its degradation in the proteasome and by transporting it out of 
the nucleus. MDM2 binds to p53 via a hydrophobic cleft in its N-terminal 
transactivation domain, burying a p53 α-helix in the hydrophobic cleft of MDM2 and 
thereby preventing the transactivation domain from interacting with the transcription  
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Figure 1.3 Cellular responses to p53 activation In response to diverse stress 
signals, p53 is activated, usually by post-translational modifications which stabilise 
the protein and prevent MDM2-mediated degradation of p53. Activated p53 then bind 
to and increase transcription of various target genes which carry out the p53 effector 
functions, including cell cycle arrest, DNA repair and apoptosis. Figure taken from 
Michalak et al [3]. 
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machinery. In addition, MDM2 acts as an E3 ligase, catalysing the mono-
ubiquitination of p53, which leads to its nuclear export and subsequent degradation 
by the proteasome in the cytoplasm. MDM2 also contains a nuclear export signal 
that allows it to directly co-transport p53 out of the nucleus into the cytoplasm [22].  
 
MDM2 itself is a target of p53’s transcriptional activity. MDM2 is therefore highly 
expressed when p53 is highly expressed and vice versa. P53 thus participates in a 
negative feedback loop with its own regulator, thereby driving its own degradation. 
MDM2-mediated ubiquitination of p53 can be reversed by the de-ubiquitination 
enzyme HAUSP (herpesvirus-associated ubiquitin-specific protease), rescuing p53 
from proteasomal degradation [29, 31]. A further factor contributing to p53 stability is 
the fact that MDM2 can catalyse its own ubiquitination and degradation, making 
MDM2 a very short-lived protein [32]. 
 
Although MDM2 is generally believed to be the principle regulator of p53, other 
cellular proteins that regulate p53 function have been identified. These include ARF, 
MDMX/MDM4, Cop1 and Pirh2. ARF (alternative reading frame product of 
p16INK4a/ARF locus) stabilises p53 by binding to MDM2 and inhibiting its ability to 
ubiquitinate p53 [30]. MDMX, a p53 binding protein with significant homology to 
MDM2, appears to work synergistically with MDM2 to enhance p53 ubiquitination. 
MDMX can bind p53 but has no ubiquitin ligase activity. It forms a RING-RING 
heterodimer with MDM2 to cooperatively ubiquitinate p53 [30, 33]. Pirh2 and Cop1 
(constitutively photomorphogenic 1) are also E3 ubiquitin ligases that catalyze the 
ubiquitination of p53 leading to its degradation [23, 34]. Like MDM2, Pirh2 and Cop1 
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expression is induced by p53 and thus these two E3 ligases also participate in 
negative feedback loops with p53. 
 
The C-terminal regulatory domain of p53 is subject to many post-translational 
modifications, particularly acetylation of lysine residues. Acetylation of lysines 305, 
320,370, 372, 373, 382 and 383 following UV or gamma irradiation, mostly by 
p300/CBP (CREB-binding protein), leads to p53 activation, enhanced sequence-
specific DNA binding and expression of p53 responsive genes [35]. Lysine residues 
370, 372, 373, 382 and 383 also appear to be the main sites of MDM2-mediated 
ubiquitination of p53 [36]. Mutation of these residues to arginine renders p53 
resistant to MDM2-mediated ubiquitination and degradation. Acetylation of K320 by 
PCAF (p300/CBP associated factor) preferentially activates the expression of cell 
cycle arrest genes, while acetylation of K120 by Tip60 and hMOF leads to the 
activation of pro-apoptotic target genes. Methylation of p53 on K372 by the 
methyltransferase Set-7/9 results in p53 activation, while methylation on K370 or 
K382 by Set-8 represses p53 activity. Other modifications of C-terminal lysines 
include sumoylation (K386) and neddylation (K320, K321, K370, K372 and K373). 
Sumoylation promotes the transcriptional activity of p53 [27], while neddylation inhibit 
the transcriptional activity of p53 [37]. 
 
1.3 The RBBP6-p53 interaction 
The identification of the p53 binding domain of RBBP6 has been complicated by 
alternative numbering schemes used by different authors. When the protein was 
initially identified in 1997 the complete sequence of the human genome had not yet 
been determined, with the result that partial transcripts of the (single) RBBP6 gene 
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were sequenced and added to the database under different names and with different 
numberings. To complicate matters further, the sequences reported in the original 
publications contain extensive errors making it difficult to correlate regions with the 
corresponding sequences currently in the database.  
 
Simons and co-workers identified residues 1220-1562 of PACT as the p53 binding 
domain [7]. As can be seen from Fig 1.4(A), this corresponds to residues 1428 to 
1761 of RBBP6. In their 2003 paper Gao and Scott identified residues 1204 to 1314 
of P2P-R as the p53 binding domain of P2P-R [9], which they were still using as the 
reference sequence despite the publication of the validated RBBP6 sequence three 
years earlier. Figure 1.4(B) shows that this corresponds to residues 1380 to 1490 of 
RBBP6. Interestingly the two regions overlap only partially (residues 1425-1490 of 
human RBBP6). 
 
Li and co-workers knocked out the mouse orthologue of RBBP6 by replacing the 
portion of the gene corresponding to residues 1017 - 1190 of the human RBBP6 
protein. The position of the fragment is not explicitly stated in their report but had to 
be inferred from the primers reported in the Material and Methods section of their 
paper [8]. Although the region is N-terminal to both of the p53 binding regions 
identified above, the transgenic procedure is likely to disrupt the entire gene, 
therefore including the putative p53 binding site.  
 
As for the region of p53 involved in the interaction, the fact that a mutation in the 
core DNA binding domain abolishes the interaction makes it likely that this is the 
region involved. However up to now this has not been conclusively demonstrated. 
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Query  1428  ESNLDRLNEQGNFKSLSQSSKEARTSDKHDSTRASSNKDFTPNRDKKTDYDTREYSSSKR  1487 
             ESNLDRLNEQGNFKSLSQSSKEARTSDKHDSTRASSNKDFTPNRDKKTDYDTREYSSSKR 
Sbjct  1     ESNLDRLNEQGNFKSLSQSSKEARTSDKHDSTRASSNKDFTPNRDKKTDYDTREYSSSKR  60 
 
Query  1488  RDEKNELTRRKDSPSRNKDSASGQKNKPREERDLPKKGTGDSKKSNSSPSRDRKPHDHKA  1547 
             RDEKNELTRRKDSPSRNKDSASGQKNKPREERDLPKKGTGDSKKSNSSPSRDRKPHDHKA 
Sbjct  61    RDEKNELTRRKDSPSRNKDSASGQKNKPREERDLPKKGTGDSKKSNSSPSRDRKPHDHKA  120 
 
Query  1548  TYDTKRPNEETKSVDKNPCKDREKHVLEARNNKESSGNKLLYILNPPETQVEKEQITGQI  1607 
             TYDTKRPNEETKSVDKNPCKDREKHVLEARNNKESSGNKLLYILNPPETQVEKEQITGQI 
Sbjct  121   TYDTKRPNEETKSVDKNPCKDREKHVLEARNNKESSGNKLLYILNPPETQVEKEQITGQI  180 
 
Query  1608  DKSTVKPKPQLSHSSRLSSDLTRETDEAAFEPDYNESDSESNVSVKEEESSGNISKDLKD  1667 
             DKSTVKPKPQLSHSSRLSSDLTRET EAAFEPDYNESDSESNVSVKEEESSGNISKDLKD 
Sbjct  181   DKSTVKPKPQLSHSSRLSSDLTRETHEAAFEPDYNESDSESNVSVKEEESSGNISKDLKD  240 
 
Query  1668  KIVEKAKESLDTAAVVQVGISRNQSHSSPSVSPSRSHSPSGSQTRSHSSSASSAESQDSK  1727 
             KIVEKAKESLDTAAVVQVGISRNQSHSSPSVSPSRSHSPSGSQTRSHSSSASSAESQDSK 
Sbjct  241   KIVEKAKESLDTAAVVQVGISRNQSHSSPSVSPSRSHSPSGSQTRSHSSSASSAESQDSK  300 
 
Query  1728  KKKKKKEKKKHKKHKKHKKHKKHAGTEVELEKSQ  1761 
             KKKKKKEKKKHKKHKKHKKHKKHAGTEVELEKSQ 
Sbjct  301   KKKKKKEKKKHKKHKKHKKHKKHAGTEVELEKSQ  334 
 
Query 1380   VSHEIIQHEVKSSKNSASSEKGKTKDRDYSVLEKENPEKRKNSTQPEKESNLDRLNEQGN  1439 
             VSHEIIQHEVKSSKNSASSEKGKTKDRDYSVLEKENPEKRKNSTQPEKESNLDRLNEQGN 
Sbjct 1      VSHEIIQHEVKSSKNSASSEKGKTKDRDYSVLEKENPEKRKNSTQPEKESNLDRLNEQGN  60 
 
Query 440    FKSLSQSSKEARTSDKHDSTRASSNKDFTPNRDKKTDYDTREYSSSKRRDE  1490 
             FKSLSQSSKEARTSDKHDSTRASSNKDFTPNRDKKTDYDTREYSSSKRRDE 
Sbjct 61     FKSLSQSSKEARTSDKHDSTRASSNKDFTPNRDKKTDYDTREYSSSKRRDE  111 
 
A 
B 
Figure 1.4 Alignment of full length human RBBP6 sequence with p53 binding 
domain sequences as reported by different authors The query sequence in (A) 
and (B) correspond to human RBBP6 isoform 1 (Acc. no. NP_008841.2), while the 
subject sequence in A corresponds to PACT (GenBank: AAL68925.1) and P2P-R 
(GenBank: AAL05625.1) in B. 
 
 
 
 
17 
 
1.4 Y-box binding protein 1 (YB-1) 
Y-box Binding Protein 1 is a multifunctional protein, which shuttles between the 
nucleus and cytoplasm. It is involved in mRNA metabolism when in the cytoplasm, 
and transactivates the expression of a number of pro-survival genes when in the 
nucleus. These include c-Myc, cyclin A and MDR1, which codes for the multi-drug 
resistance factor P-glycoprotein and confers chemotherapeutic resistance during 
cancer treatment [38-42]. Several clinical studies have implicated YB-1 in 
tumourigenesis, tumour cell progression and poor patient outcome. 
 
Human YB-1 was originally identified in a screen for transcription factors binding 
promoters of MHC (major histocompatibility complex) class II genes [43]. YB-1 
specifically binds to the inverted CCAAT box (Y-box) of the HLA-DR α chain gene. 
YB-1 has subsequently been characterised as a member of the cold shock domain 
(CSD) superfamily due to the presence of the highly conserved cold shock domain. 
The cold shock domain is an evolutionary conserved domain occurring in organisms 
ranging from bacteria to humans [44]. In bacteria CSD proteins function as RNA 
chaperones, destabilising RNA secondary structure and controlling translation at low 
temperatures [45, 46]. 
 
In humans three Y-box binding proteins have been identified, namely dbpA, 
dbpC/contrin and dbpB/YB-1 [47]. Y-box proteins have three domains: the highly 
conserved CSD, flanked by variable N- and C-terminal domains [48]. The CSD is a 
nucleic acid binding domain, mediating binding to RNA as well as single- and 
double-stranded DNA. The C-terminal domain consists of alternating stretches of 
basic and acidic residues of about 30 residues long, called the B/A repeat. The 
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highly charged C-terminal tail mediates protein-protein interactions, causes 
multimerization of YB-1 and has a strong affinity for single-stranded DNA [49].  The 
N-terminal domain is rich in alanine and proline residues and is responsible for the 
transactivation of YB-1 responsive genes [48]. Figure 1.5, taken from Skabkin and 
co-workers, shows the domain organisation and functions of YB-1 [50]. 
 
YB-1 functions both as a transcription factor and a translational regulator [48]. YB-1 
responsive genes include multidrug resistance gene 1 (MDR1), c-Myc, matrix 
metalloprotein-2 (MMP-2), cyclin A and cyclin B1, epidermal growth factor receptor 
and p53 among others [47, 51]. As a transcriptional regulator YB-1 functions as both 
a transcriptional activator and repressor. In the case of p53 YB-1 acts as a 
transcriptional repressor, as demonstrated by Lasham and co-workers [51]. The 
authors showed that YB-1 represses the p53 promoter by binding to Y-box 
sequences in the promoter, thereby down-regulating the expression of endogenous 
p53. At the G1/S transition YB-1 translocates to the nucleus and activates 
transcription of cyclin A and cyclin B1; thereby playing a role in regulation of the cell 
cycle [52].  
 
Several studies have shown that YB- 1 up-regulates MDR1 gene expression in 
response to UV radiation and chemotherapeutic drugs such as doxorubicin and 
cisplatin [53, 54]. The MDR1 gene encodes the ATP-dependent drug efflux pump P-
glycoprotein, which excretes chemotherapeutic drugs such as doxorubicin and 
cisplatin. In response to anti-cancer drugs or UV radiation cytoplasmic YB-1 
becomes activated and translocates to the nucleus where it up-regulates MDR1 
expression. 
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Figure 1.5 Domain organization and functions of YB-1 YB-1 has three domains: an 
N-terminal domain rich in alanine and proline residues, the highly conserved cold shock 
domain and the C-terminal domain which contains stretches of alternating basic and 
acidic residues. The CSD and C-terminal domain has high affinity for RNA and DNA. 
Ser102 is phosphorylated by Akt kinase to activate the transcriptional activity of YB-1. 
Figure taken from Skabkin and co-workers [47]. 
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YB-1-induced MDR1 expression is thus associated with lower susceptibility to 
chemotherapeutic drugs and an unfavourable clinical outcome [55].  
 
Almost all cytoplasmic mRNA in the cell is found in complex with YB-1. YB-1 has a 
very high affinity for RNA, mediated both by the CSD and the C-terminal domain. 
The CSD contains two RNA binding motifs, designated RNP1 and RNP2. Newly 
formed mRNA is immediately bound by proteins to form a heterogeneous 
ribonucleoprotein (hnRNP), also denoted pre-mRNP. Along with the poly(A) binding 
protein 1 (PABP1), YB-1 is the most abundant protein found in hnRNP complexes 
[56]. YB-1 remains associated with mRNA, shuttling mRNA to the cytoplasm [56].  
YB-1  has been shown to both promote and inhibit translation depending on the 
concentration of YB-1: at high concentrations YB-1 blocks translation while at a low 
YB-1/mRNA ratio translation is stimulated [57].  
 
YB-1 inhibits translation at the initiation stage by blocking the interaction of the 
translation factor eIF4G with mRNA [58]. YB-1 has also been shown to function as a 
pre-mRNA splicing factor [59, 60]. YB-1 binds to A/C-rich exon enhancers (ACE), 
which are exon splicing signals and participate in alternative splicing of CD44 [61]. 
CD44 is a cell surface antigen, involved in cell–cell interactions, cell adhesion and 
migration [62, 63].  
 
Regulation of YB-1 
YB-1 function is subject to several modes of regulation. At the transcriptional level, 
several transcription factors that bind to YB-1 promoter sequences to activate YB-1 
transcription have been identified, including p73, c-Myc, Twist, GATA-1 and GATA-2 
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[64-66]. At the translational level, YB-1 has been shown to autoregulate the 
translation of its own mRNA [67-72]. P73 is a close relative of p53 [73, 74]; like p53, 
activated p73 can induce cell cycle arrest or apoptosis. In response to cisplatin 
treatment p73 indirectly activates YB-1 expression by binding to the C-terminal 
domain of c-Myc, thereby promoting the binding of c-Myc to YB-1 promoter 
elements, leading to transcriptional activation of YB-1. Twist, an E-box binding 
transcription factor, also activates YB-1 transcription in response to cisplatin 
treatment. E-boxes are regulatory elements that occur in the promoters of some 
genes, including YB-1 [75].  
 
YB-1 has been shown to inhibit translation of its own mRNA by inhibiting the binding 
of the translation initiation factor PABP1 [69]. PABP1 stimulates initiation of protein 
synthesis by binding to the poly(A) tail of mRNA and interacting with the initiation 
factors eIF4G, eIF4B and Paip (PABP-interacting protein) 1 [76]. The binding sites 
for YB-1 and PABP1 on YB-1 mRNA overlap; binding of YB-1 to its own mRNA 
prevents PABP1 from binding to and initiating YB-1 mRNA translation.    
 
At the post-translational level, YB-1 is subject to phosphorylation by the 
serine/threonine kinase Akt on serine 102. Akt mediates downstream 
phosphorylation cascades in response to growth factors, cytokines, and other 
cellular stimuli [77], enhancing the survival of cells by blocking the function of pro-
apoptotic proteins and processes. Akt-mediated phosphorylation causes YB-1 to 
translocate to the nucleus where it activates gene expression [72]. In addition, Akt 
phosphorylation of YB-1 at Ser102 also relieves the translational repressive effect of 
YB-1 by inhibiting the binding of YB-1 to the 5’ cap of mRNA [78].   
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According to the standard model of activation of YB-1, YB-1 is cleaved by the 20S 
proteasome in an ubiquitination-independent manner, leading to translocation of the 
N-terminal fragment into the nucleus where it activates transcription [71]. Cleavage 
of YB-1 occurs between residues Glu219 and Gly220, thereby removing a C-
terminally located cytoplasmic retention signal. This generally accepted model of YB-
1 activation has recently been challenged by work published by Braithwaite and co-
workers [79, 80], who have reported that nuclear translocation of YB-1 in response to 
genotoxic stress occurs in the absence of proteolytic cleavage.  
 
YB-1 cellular levels are also regulated by ubiquitin-mediated proteasomal 
degradation, stimulated by the E3 ligases FBX33 (F-Box protein 33) and RBBP6 [67, 
70]. FBX33 binds to YB-1 and recruits it to a SCF-E3 ligase complex, which 
ubiquitinates it, leading to its proteasomal degradation. More recently, RBBP6 was 
also shown to promote ubiquitination and proteasomal degradation of YB-1 [70]. The 
C-terminus of YB-1 was identified using a yeast two hybrid screen as interacting 
directly with the RING finger domain of RBBP6. Overexpressing of either the isolated 
RING finger or full length RBBP6 was subsequently shown to reduce cellular levels 
of YB-1 in a proteasome-dependent manner. 
 
1.5 The ubiquitin-proteasome system (UPS) 
Ubiquitination, the covalent attachment of ubiquitin molecules to cellular proteins, 
serves diverse cellular functions including protein degradation, signalling, sorting, 
localization, transcriptional regulation, cell cycle progression and DNA repair [81-83]. 
Deregulation of the ubiquitin-proteasome system can cause pathological conditions 
including cancer, autoimmune diseases, neurodegenerative disorders and 
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developmental abnormalities [84, 85]. Components of the system include ubiquitin 
activating enzymes (E1), the ubiquitin conjugating enzymes (E2), ligase enzymes 
(E3) and the 26S proteasome [86].  
 
Figure 1.6 diagrammatically illustrates the process of ubiquitin-mediated protein 
turnover [5]. Substrate ubiquitination follows the following enzymatic cascade: the E1 
utilizes ATP to form a high energy thiol ester bond between the C-terminus of 
ubiquitin and a catalytic cysteine on the E1. Ubiquitin is then transferred to the E2, 
forming a thiol ester linkage between the C-terminus of ubiquitin and a catalytic 
cysteine on the E2. Finally the ubiquitin is transferred to a lysine on the substrate, 
forming an isopeptide bond between the C-terminus of ubiquitin and the NH3+ group 
on the side-chain of the catalytic lysine. In the case of RING E3s the role of the E3 is 
simply to bring the ubiquitin-conjugated E2 and the substrate into close proximity in 
order to facilitate transfer of ubiquitin. The situation is a little more complicated in the 
case of HECT domain-containing E3s, where the ubiquitin becomes covalently linked 
to the E3 via a thiol ester bond involving a catalytic cysteine on the E3, before being 
transferred to the substrate.  Poly-ubiquitinated substrates, with 4 or more ubiquitin 
molecules attached, are recognised by the proteasome, a large multi-subunit 
proteolytic complex, which degrades ubiquitin-tagged proteins [5]. 
 
The 26S proteasome is a 2.5 megadalton multi-protein complex, consisting of two 
large complexes, the 19S regulatory particle (RP) and the 20S core particle (CP). 
The 20S CP consists of four heptameric rings, two outer rings formed by 7 α-
subunits each and two inner rings formed by 7 β-subunits each, stacked in an  
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Figure 1.6 The ubiquitin-proteasome system of protein degradation and processing 
Ubiquitin is first activated by the E1 enzyme, followed by transfer to the E2 enzyme to form a 
high-energy E2~Ub thioester complex. The E2~Ub complex is recognised and recruited by 
the E3 ligase which also binds the substrate. In the final step of the conjugation cascade 
ubiquitin is transfer to a lysine residue on the substrate. Formation of a polyubiquitin chain on 
the substrate leads to its recognition by the proteasome where it is degraded. Ubiquitin is 
released from the substrate to participate in further substrate tagging. Figure adapted from 
Zheng et al [5] 
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α7β7β7α7 conformation [87]. The 19S regulatory particle recognises poly-ubiquitinated 
substrates and uses ATP to unfold and feed them into the 20s core particle.  
 
Prokaryotic 20S CP consists of 14 identical -subunits and 14 identical -subunits, 
with the proteolytic activity residing in the -subunits. These -subunits possess 
chymotrypsin-like activity, cleaving only after hydrophobic residues [88, 89]. In 
contrast, the eukaryotic 20S CP has 14 different -subunits and 14 different -
subunits [83]. The -subunits of eukaryotic proteasomes display additional 
proteolytic specificity, namely caspase-like (cleavage after acidic residues) and 
trypsin-like (cleavage after basic residues) activity [90]. 
 
Ubiquitination enzymes 
(i) Ubiquitin-activating enzyme (E1) 
The ubiquitin-activating enzyme lies at the apex of the ubiquitination cascade. 
Surprisingly, for the majority of eukaryotic organisms only a single gene coding for 
the ubiquitin E1 enzyme is known. In humans two E1 enzymes have been identified 
to date, namely UBA1/UBE1 and UBA6/UBE1L2 [91, 92]. UBA1 is ubiquitously 
expressed, while UBA6 expression °occurs predominantly in the testis.  
 
Ubiquitin activation by the E1 is well characterised [93, 94]. First, E1 associates with 
ubiquitin and catalyzes the adenylation of the C-terminal glycine of ubiquitin in an 
ATP-dependent process. Second, E1 forms a thioester between a conserved 
catalytic cysteine and ubiquitin. Next, E1 is loaded with a second ubiquitin molecule, 
followed by its C-terminal adenylation. Finally, the ternary E1~Ub thioester complex 
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recruits an E2 to facilitate transfer of the thioester-linked ubiquitin to a conserved 
cysteine on the E2.  
 
(ii) Ubiquitin-conjugating enzymes (E2s) 
The E2 family consists of l6 genes in S. cerevisiae and at least 38 genes in humans 
[95, 96]. Most E2 family members share the core ~150-200 amino acid ubiquitin 
conjugation domain (UBC), which contains the catalytic cysteine residue and which 
interacts with the E1 [97]. The UBCs of different E2s have a high degree of 
sequence homology and adopt a similar fold, which consists of four α-helices, an 
anti-parallel β-sheet formed by four strands, and a short 310-helix. The UBC provides 
a binding platform for the E1, the E3 and activated ubiquitin. In addition to the 
catalytic core domain, most E2s possess N- or C-terminal extensions which 
contribute to the specificity of E1 binding, determine subcellular localisation or 
modulate the interaction with E3s. E2s are classified into 4 classes based on these 
extensions: class I E2s consist of the UBC only, classes II and III have N- and C-
terminal extensions respectively, while class IV E2s have both N-terminal and C-
terminal extensions [96].  
 
Overwhelming evidence has emerged showing that E2s select the type of poly-
ubiquitin chain linkage attached to substrate proteins [98, 99]. Ubiquitin has 7 
internal lysine residues, each of which is a potential site for ubiquitin polymerization. 
The type of ubiquitin linkage in turn determines the cellular fate of the poly-
ubiquitinated substrate protein; for example Lys48-linked ubiquitin chains target 
substrates for proteasomal degradation while Lys63 linkages mediate the activation 
of NF-B or activate DNA repair pathways [96, 100]. 
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(iii) Ubiquitin ligases (E3s)  
Since ubiquitin ligases interact directly with the substrates of the UPS, it is they that 
determine the specificity. E3s act not only as scaffolds for substrate ubiquitination 
but also directly catalyse the transfer of ubiquitin from the E2 to the substrate [101]. It 
was recently shown that RING E3 ligases are responsible for selecting the target 
lysine on the substrate [102]. While the E2 enzyme is sufficient to catalyze substrate 
poly-ubiquitination, the target lysine chosen for ubiquitination is promiscuous. The E3 
is required to determine the correct ubiquitination site and to confer specificity on the 
E2 enzyme activity.   
 
Ubiquitin ligases are grouped into three classes: RING (Really Interesting New 
Gene)-containing, HECT (Homologous to E6-AP Carboxyl Terminus)-containing, and 
the U-box- containing E3s. RING-containing E3s constitute the largest group, with 
more than 600 members being identified through bioinformatic analysis of the human 
genome, while only about 30 HECT domain E3 ligases have been identified [103].  
 
The RING domain fold is generally described as a  fold and is defined by the 
following sequence motif: Cys-X2-Cys-X(9-39)-Cys-X(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)-
Cys-X2-Cys (where X is any amino acid) [104]. The domain coordinates two zinc ions 
in a cross-brace motif. The zinc ions are coordinated to the sulphur of the conserved 
cysteines and the imidazole ring of the histidine. These conserved residues are 
buried in the hydrophobic core of the domain and help maintain the overall structure 
of the domain. RING variants in which the conserved Cys and His residues are 
swapped or replaced by other zinc coordinating residues like aspartic acid also 
occur.  
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The U-box adopts the same overall fold as the RING domain but does not coordinate 
zinc ions [105-107]. Instead the fold is stabilised by a network of salt-bridges and 
hydrogen bonds. Originally, U-box-containing proteins were thought to act as 
accessory factors in RING or HECT domain mediated ubiquitination, acting as so-
called E4 ligases [107]. However it has since been established that U-box proteins 
are able to catalyze poly-ubiquitination of substrates independent of HECT or RING 
domain E3s, thereby acting as bona fide E3s [107, 108].   
 
The HECT domain is a large domain of about 350 residues. The domain has a large 
N-terminal lobe containing the E2-binding site and a smaller C-terminal lobe which 
includes the active site cysteine. The two lobes are connected by a flexible hinge 
region which juxtaposes the catalytic cysteine residues of the E2 and E3 enzymes 
during ubiquitin transfer [109]. Deletion or mutation of residues in the hinge region 
abolishes ligase activity of HECT domain proteins. Unlike RING and U-box E3 
ligases, HECT domain-containing E3s possess intrinsic catalytic activity. The domain 
catalyses ubiquitin transfer in three steps: binding to an E2, loading ubiquitin onto 
themselves through the formation of an ubiquitin-thioester intermediate with the 
catalytic cysteine and transfer of ubiquitin to the target protein [109]. 
 
HECT domain E3s are frequently associated with cancer development. The founding 
member of the family, E6-AP (E6 associated protein), is a 100 kDa protein that 
interacts with the E6 protein of the cervical cancer-related human papillomavirus 
(HPV) [110, 111]. E6-AP forms a stable dimer with E6, which binds to and targets 
p53 for proteasome-mediated degradation. In a study conducted by Chen and co-
workers ARF-BP1, another HECT domain E3 ligase, also targets p53 for 
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degradation, thereby abrogating the tumour suppressive function of  p53 [112]. ARF-
BP1 is highly expressed in lung and breast carcinomas. Knockdown of endogenous 
ARF-BP1 stabilises p53 and induces both growth arrest and apoptosis.  
 
1.6 Aims of the study 
As the preceding discussion has shown, RBBP6 interacts with both p53 and YB-1, 
modulating the DNA-binding of p53 and catalysing the ubiquitination and 
proteasomal degradation of YB-1, among other reported effects. However the sites 
of interaction between RBBP6 and p53 are poorly defined in the literature, and due 
to their size and marginal stability the full length proteins are difficult to work with in 
vitro. It would therefore be desirable to identify the domains responsible for the 
interaction and express them in bacterial systems. 
 
Although RBBP6 has been shown to promote ubiquitination of YB-1 in vivo, it is not 
clear whether RBBP6 is directly involved in catalysing the ubiquitination or whether 
additional factors are supplied by the cellular environment. It would therefore be 
desirable to reconstitute the ubiquitination in vitro. An in vitro assay would also 
facilitate future investigations of the effect of mutations on the ubiquitination activity 
of RBBP6. 
 
The aims of this study are therefore two-fold: 
 To characterize the interaction between RBBP6 and p53 with the aim of 
localising the regions of interaction on each protein and identifying the 
specific amino acids involved in the interaction. 
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 To investigate ubiquitination of YB-1 by RBBP6 using bacterially expressed 
proteins and a fully in vitro reaction system.  
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Chapter 2: Materials and methods 
2.1 Materials and suppliers 
40% 37.5:1 acrylamide: bis-acrylamide   Promega 
Agarose       Promega 
Ammonium persulphate     Merck 
Ampicillin       Roche 
Antibodies       Santa Cruz Biotechnology 
Boric acid       Merck 
Bovine serum albumin     Roche 
Calcium chloride      Merck 
Chloramphenicol      Sigma 
Coomassie Blue R-250     Sigma 
DNAse I       Sigma 
Ethanol       BDH 
Ethidium bromide      Sigma 
Ethylene diamine tetra acetic acid (EDTA)   Merck 
GFX DNA purification kit     Amersham Biosciences 
Glacial acetic acid      Merck 
Glycerol       BDH 
Glycine       Merck 
Hydrochloric acid      Merck 
Imidazole       Sigma 
Isopropanol       Merck 
Kanamycin mono-phosphate    Roche  
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Magnesium chloride     Merck 
Methanol       Merck 
N, N, N’, N’-Tetra methylethylene-diamine (TEMED) Promega 
Nutrient agar       Merck 
Potassium acetate      Merck 
Potassium chloride      Merck 
Protease inhibitor cocktail     Roche 
QuantiTect cDNA synthesis kit    Qiagen 
Restriction enzymes     Fermentas 
RNAse A       Roche 
Sodium chloride      Merck 
Sodium dodecyl sulphate     Promega 
T4 ligase       Fermentas 
Tissue culture media and reagents   Gibco BRL 
Tris [hydroxymethyl] aminomethane   BDH 
Triton X-100       Fluka 
TRIzolR reagent      Gibco life technologies 
Tryptone       Merck 
Wizard SV DNA preparation kit    Promega 
Yeast extract       Merck 
Glutathione agarose     Sigma 
Nickel sepharose      Amersham Biosciences 
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2.2 General stock solutions and buffers 
Buffer Composition/ Preparation 
10x DNAse buffer 0.5 M Tris pH 7.5, 0.1 M MnCl2, 0.5 mg/ml BSA. This buffer was        
diluted ten-fold to prepare DNAse I 
10x TBE 0.9 M Tris (pH 8.3), 0.89 M boric acid and 25 mM EDTA. This 
stock was stored at room temperature and diluted ten-fold for 
running agarose gels. 
2X SDS gel 
sample buffer 
4% SDS, 0.125 M Tris pH 6.8, 15% glycerol and 1 mg/ml 
bromophenol blue. This buffer was stored at room temperature. 
10 % - mercaptoethanol was added to the buffer immediately 
prior use. 
5x SDS 
electrophoresis 
buffer 
25 mM Tris, 0.1% SDS and 250 mM glycine, pH 8.3. 
 
Ampicillin A 100 mg/ml solution was made in deionised water, filter-
sterilised   and stored at -20 °C. 
Cell lysis buffer 50 mM Tris, pH 8.0, 200 mM NaCl, 0.5% Triton X-100, 20 mM -
mercaptoethanol, CompleteTM EDTA-free protease inhibitor 
cocktail, 50 g/ml DNAse I, 100g/ml lysozyme. 
 
Destaining 
solution 
40% ethanol, 10% acetic acid. 
 
Gel staining 
solution 
40% ethanol, 10% acetic acid, 0.1% Coomassie Blue R-250. 
 
Glycerol BPB 30 % glycerol (v/v), 15 mM EDTA (pH 8.0) and 0.5 % 
bromophenol blue (w/v).  
 
IPTG A 0.1 M stock solution was prepared in deionised water, filter-
sterilised and stored at -20 °C. 
 
Kanamycin A 50 mg/ml stock solution was prepared in deionised water and        
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stored at -20 °C. 
Luria broth 1 % tryptone, 0.5 % yeast extract, 0.5 % NaCl and 0.2 % 
glucose. 
RNAse A A 20 mg/ml stock solution was prepared in a buffer containing 
0.1 M   sodium acetate and 0.3 mM EDTA (pH adjusted to 4.8 
with acetic acid). This solution was boiled for 15 minutes and 
cooled quickly by placing it in ice water and stored at -20 °C. 
 
Tbf1 30 mM potassium acetate, 50 mM MnCl2, 0.1 M KCl, 10 mM 
CaCl2 and 15 % glycerol (v/v).                            
Tbf2 9 mM Na-MOPS, 50 mM CaCl2, 10 mM KCl and 15 % glycerol 
(v/v). 
TE 10 mM Tris, 1 mM EDTA adjusted to pH 7.4 with HCl. 
 
TYM 20 % tryptone, 0.5 % yeast extract, 0.1 m NaCl, 0.2 % glucose 
and 10 mM MgCl2. 
 
3C protease 
buffer 
50 mM Tris, pH 8.0, 200 mM NaCl, 20 mM -mercaptoethanol. 
Tev protease 
buffer 
50 mM Tris, pH 8.0, 200 mM NaCl, 20 mM -mercaptoethanol,      
40 mM imidazole. 
 
 
Table 2.1 General stock solutions and buffers 
2.3 Bacterial culture 
2.3.1 Bacterial strains 
Escherichia coli strain MC1061:  
F- araD139 D(ara-leu) 7696 galE15 galK16 D(lac)X74 rpsL (Strr) hsdR2 (rK_ mK+) 
mcrA mcrB1. This strain was used to produce plasmid DNA. 
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Escherichia coli strain BL21 (DE3)pLysS: 
F- ompT gal dcm lon hsdSB(rB- mB-) λ(DE3) pLysS(cmR). This strain was used to 
express recombinant proteins.  
 
Escherichia coli strain Rosetta 2TM (DE): 
F- ompT hsdSB(rB- mB-) gal dcm (DE3) pRARE2 (CamR). This strain was used for   
recombinant protein expression. 
 
2.3.2 Antibiotic selection 
For experiments with E. coli containing ampicillin or kanamycin resistant plasmids, 
transformed cells were plated on nutrient agar with ampicillin at 100 μg/ml and 
kanamycin at 25 μg/ml. Selection was maintained during growth in liquid culture by 
the inclusion of the appropriate antibiotic at the same concentration. 
 
2.4 Preparation of competent E. coli cells for transformation 
The desired bacterial strain was streaked out on a nutrient agar plate containing 10 
mM MgCl2 or MgSO4 and incubated overnight at 37 °C. A single colony was picked 
and used to inoculate 20 ml of TYM broth and grown with vigorous shaking at 37 °C 
until the optical density (OD) at 550 nm reached 0.2. The cells were then transferred 
to 100 ml of TYM broth and grown at 37 °C until the optical density at 550 nm 
reached 0.2. To this culture 400 ml of fresh TYM broth was added and the cells were 
grown under the same conditions until the optical density at 550 nm was in the range 
0.4-0.6. The cells were rapidly chilled in ice water, with swirling, transferred to a 250 
ml tube and pelleted by centrifugation at 6000 g for 10 min in a pre-cooled Beckman 
J2-14 rotor. After removing the supernatant the cells were re-suspended in 250 ml 
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ice cold Tfb1 and allowed to incubate at 0 °C for 30 min. The cells were recovered by 
centrifugation at 6000 g for 8 min. The supernatant was removed and the pellet was 
re-suspended in 30 ml ice cold Tfb2. Cells were frozen in liquid nitrogen as 300 μl 
aliquots and stored at – 80 °C. 
 
2.5 Bacterial transformations  
For DNA transformations competent cells (prepared as described in the Section 2.4)  
were thawed on ice and 100 μl were added to 100-500 ng of the plasmid DNA 
solution, gently mixed and incubated for 30 min on ice. The cells were heat shocked 
by transfer to a 37 °C water bath for 5 minutes, after which 500 μl of pre-warmed LB 
broth was added and the mixture incubated at 37 °C for an hour to allow for the 
expression of the antibiotic resistance marker. The transformed cells (100-200 μl) 
were then plated onto pre-warmed nutrient agar plates containing the appropriate 
antibiotic and the plates incubated overnight at 37 °C. 
 
2.6 Preparation and manipulation of DNA 
2.6.1 Isolation of plasmid DNA 
A single colony of transformed E. coli was inoculated into 5-10 ml of LB containing 
the appropriate antibiotic. The inoculated broth was incubated at 37 °C with vigorous 
shaking for 16 hours after which the cells were pelleted by centrifugation at 16000 g 
for 10 minutes in a Beckman bench top centrifuge with a fixed-angle rotor. Plasmid 
DNA was isolated using the Wizard SV plasmid isolation kit (Promega), according to 
the manufacturer’s instructions. 
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2.6.2 PCR amplification of gene fragments 
Generally, reactions consisted of 50-100 ng template DNA, 1x PCR buffer, 0.25 mM 
of each dNTP, 2U Taq DNA polymerase and 10 pmol of forward and reverse gene 
specific oligonucleotides, in a final volume of 50 μl. 
 
Oligonucleotide melting temperatures (Tm) were calculated using the online tool 
Oligo Calc found at www.basic.northwestern.edu/biotools/oligocalc.html and thermal 
cycling was carried out using the following procedure: 
 
96 °C for 2 minutes (Initial denaturation) 
94 °C for 1 min (Denaturation) 
(Tm -5 °C) for 1 min (Annealing) 
72 °C for 2 min (Extension) 
72 °C for 5 min (Final extension) 
 
PCR reaction products were analysed by electrophoresis in 1x TBE on 0.8-1 % 
agarose gels.  
 
2.6.3 Restriction enzyme digestion of DNA 
Restriction enzymes were used according to the manufacturer’s instructions. 
Generally, 1-2 μg of plasmid DNA or PCR products were digested with 10 units of 
the desired restriction enzymes in a 100 μl reaction volume. Reactions were 
incubated at the appropriate temperature for 1 hour. Digested DNA was purified 
using the GFX DNA purification kit (AEC-Amersham). 100 μl of DNA was mixed with 
500 μl of capture buffer in a GFX column within a collection tube and centrifuged for 
30 cycles 
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30 seconds at 16 000 g. The flow through was discarded and the column placed 
back in the collection tube. 500 μl of wash buffer was added to the column and the 
tube centrifuged for 1 min at 16 000 g. The collection tube was removed and the 
column placed in a 1.5 ml tube. 100 μl of elution buffer (TE or distilled water) was 
placed directly on the matrix of the column and allowed to incubate at room 
temperature for 1 min. The tube was centrifuged for 1 min at 13 000 g to collect the 
DNA.  
 
2.6.4 Annealing of oligonucleotides 
Equimolar quantities of complementary oligonucleotides were mixed in annealing 
buffer (10mM Tris pH7.4, 0.1mM EDTA) at a concentration of 0.2 g/l. The mixture 
was incubated at 96 °C for 5 minutes and allowed to cool down to room temperature 
for 2 hours to allow for the formation of double-stranded DNAs. 
 
2.6.5 Ligation of DNA 
Vectors used for cloning were prepared as described in Section 2.6.1. The plasmid 
DNA was digested with the appropriate restriction enzymes as described in Section 
2.6.2. In general, vectors were digested with different enzymes, leaving non-
compatible ends. These vectors were used directly in ligation reactions, following 
purification to remove the restriction enzymes. Generally, 50-100 ng of cloning 
vectors were used for ligations. Both the cloning vectors and inserts were purified 
using a GFX DNA purification kit. Ligations were set up in 20 μl reaction volumes 
containing 2 μl of 10x buffer and 1.0 Weiss unit of T4 ligase. Ligation reactions were 
allowed to proceed at 4 °C overnight. 
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2.6.6 Agarose gel electrophoresis of DNA 
DNA was size-fractionated by agarose gel electrophoresis on 0.8-1 % gels 
containing 0.5 μg/ml ethidium bromide and electrophoresed in 1x TBE buffer. DNA 
size markers were loaded alongside the samples to estimate the size of DNA 
fragments. After electrophoresis the DNA was visualised and photographed using a 
Bio-Rad Gel D°C XR imaging system.  
 
2.7 Cell Culture 
2.7.1 Cell line 
HEK293T cells were used in this project. This cell line was established from human 
primary embryonic kidney cells transformed by a type 5 adenovirus. HEK293T cells 
are an adherent fibroblastoid line growing as a monolayer. Cells were cultured in 
RPMI containing 10 % foetal calf serum (FCS). 
 
2.7.2 Tissue culture media 
The following tissue culture media and supplements were supplied by Gibco BRL: 
RPMI 1640 with Glutamax-L, 100x penicillin-streptomycin (P/S), foetal calf serum 
(FCS) and phosphate buffered saline (PBS) (pH 7.0). Working solutions of 0.125% 
trypsin and 10x P/S were prepared using sterile PBS. 
 
2.7.3 Propagation of cell lines 
Cells were grown in complete media, 1x P/S and 10 % (v/v) FCS in a 37 °C incubator 
in 5 % CO2 atmosphere until confluency was reached. Cells were treated with trypsin 
and pelleted by centrifugation at 3000 g for 5 minutes.  
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2.8 RNA isolation 
Total RNA was isolated from cultured cells using the TRIzolR protocol from Gibco 
Life Technologies. Cells grown in monolayer were homogenised by the addition of 
0.2 ml TRIzolR reagent per 10 cm3 culture flask. The homogenate was transferred to 
a 15 ml conical tube and 0.2 ml of chloroform per 0.75 ml of TRIzolR reagent was 
added. The solution was vigorously shaken for 15 seconds and allowed to incubate 
at room temperature for 10 min. The sample was then centrifuged for 30 minutes at 
3000 g at 4 °C to allow phase separation. The top aqueous phase was transferred to 
a fresh conical tube and mixed with 0.5 ml of isopropanol per 0.75 ml of TRIzolR 
reagent to allow for RNA precipitation. The sample was incubated at room 
temperature for 15 min and centrifuged for 30 min at 3000 g at 4 °C. The resulting 
pellet was washed with 1 ml 70 % ethanol per 0.75 ml of TRIzolR reagent. The pellet 
was allowed to dry at room temperature and re-suspended in 100 μl nuclease-free 
water. The isolated RNA was stored at -80 °C. 
 
2.9 cDNA synthesis 
For first strand cDNA synthesis, the QuantiTectR Reverse Transcription kit (Qiagen) 
was used. First, genomic DNA was eliminated from the isolated RNA by mixing the 
reagents listed in Table 2.2.  
 
The reaction mixture was incubated at 42 °C for 2 minutes and then placed on ice. 
The reaction mixture was used directly in the cDNA synthesis reaction, using the 
primer mixture included in the QuantiTectR Reverse Transcription kit. 
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Reagent Volume Concentration 
7x gDNA WipeOut buffer 2 l 1x 
RNA template 1 l 100 ng/l 
RNAse-free water 11 l - 
Total volume 14 l - 
Table 2.2 Reaction mixture used to eliminate genomic DNA from isolated RNA 
 
 
The reaction for first strand cDNA synthesis consisted of the following reagents:  
Reagent Volume Concentration 
RT Primer Mix 1l - 
Reverse transcriptase 1 l - 
5x Buffer 4 l 1x 
Template RNA 14 l (from gDNA 
elimination reaction) 
- 
Total volume 20l - 
Table 2.3 Reagents used for the first strand cDNA synthesis reaction 
 
The reaction mixture was mixed by briefly vortexing, centrifuged and then incubated 
at 45 °C for 15 minutes. The reverse transcriptase was inactivated by incubation at 
95 °C for 3 minutes and the reaction mixture cooled on ice before storage of the 
cDNA at -20 °C.  
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2.10 Site directed mutagenesis 
Site directed mutagenesis was performed using a PhusionTM Site Directed 
Mutagenesis kit (Finnzymes) according to the manufacturer’s instructions. A pair of 
adjacent primers, incorporating the desired mutation in the nucleotide sequence was 
mixed with the components listed in Table 2.4 and thermal cycling carried out as 
follows: 
98 °C for 2 minutes (Initial denaturation) 
98 °C for 1 minute (Denaturation) 
65 °C for 45 seconds (Annealing) 
72 °C for 3 minutes (Extension) 
72 °C for 10 minutes (Final extension)  
 
Component Volume Final concentration 
dH2O 35.5 μl  
5x PhusionTM HF buffer 10 μl 1x 
dNTPs 1 μl 200 μM 
Primer 1 (R273H 1 Table 
3.3) 
1 μl 0.5 μM 
Primer 2 (R273H 2 Table 
3.3) 
1 μl 0.5 μM 
Template 1 μl 2 ng/l 
PhusionTM Hot start 
polymerase 
0.5 μl  0.02 U/ μl 
Total 50 μl  
  Table 2.4 Site directed mutagenesis PCR reaction mixture 
25 cycles 
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The resulting PCR product was ligated and used to transform E. coli MC1061 and 
plasmid DNA isolated as described. Introduction of the mutation was confirmed by 
direct DNA sequencing. 
 
2.11 Recombinant protein expression 
2.11.1 Protein expression in rich media 
E. coli cells transformed with expression constructs were grown overnight at 37 °C 
on nutrient agar plates containing the appropriate antibiotics. Single colonies were 
picked and used to inoculate 100 ml of LB containing the appropriate antibiotics. This 
culture was grown overnight at 37 °C on a rotary shaker. The culture was scaled up 
to 1 litre by the addition of 900 ml of LB medium containing the appropriate antibiotic 
and grown at 37 °C until the culture reached an optical density at 550 nm of 0.5. 
Recombinant protein expression was induced by the addition of IPTG to a final 
concentration of 0.5 mM. Induction was carried out overnight at 30 °C. Overnight 
cultures were transferred to 250 ml polypropylene tubes and the cells harvested by 
centrifugation at 3000 g for 30 minutes at 4 °C.  Cell pellets were stored at -80 °C.  
 
2.11.2 Protein expression in labelled media 
For 15N labelling of recombinant protein, proteins were expressed in minimal medium 
(12.8 g/l Na2HPO4-7H2O, 3 g/l KH2PO4, 0.5 g/l NaCl and 2 ml 1M MgSO4, 0.1 ml 1M 
CaCl2) supplemented with 1g/l 15N-H4Cl (Spectra Gas) as the sole nitrogen source. 
Expression was carried out as described in Section 2.11.1.  
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2.11.3 Protein extraction 
Cell pellets were thawed on ice and resuspended in lysis buffer containing 50 mM 
Tris, pH 8.0, 200 mM NaCl, 20 mM -mercaptoethanol, 100 g/ml lysozyme, 50 
g/ml DNAse I, 25 g/ml RNAse A, 0.5 % Triton X-100 and 1x CompleteTM EDTA- 
free protease inhibitor cocktail (Roche). For the purification of histidine fusion protein, 
40 mM imidazole was included in the extraction buffer. Cells were lysed on ice by 
sonication. Sonication was carried out in 15 second bursts, followed by 15 seconds 
rest, repeated for 10 minutes. The lysates were cleared by centrifugation at 5000 g 
for 30 minutes at 4 °C.  
 
2.11.4 Protein purification 
2.11.4.1 Column preparation  
Glutathione affinity chromatography using a self-packed gravity-flow column was 
used for the purification of GST-tagged recombinant proteins. Glutathione agarose 
beads (Sigma) were prepared according to the manufacturer’s instructions. A Nickel 
Sepharose™ High Performance column (Amersham Biosciences) was used for the 
purification of 6xHis-MBP tagged proteins.  
 
 2.11.4.2 Purification of the crude cell lysate  
The appropriate column (Glutathione agarose or Nickel Sepharose) was washed 
with 3 column volumes (CV) of 1 M NaCl and then equilibrated with 5 CV of wash 
buffer. The crude lysate was added to the column and the flow through collected. 
The column was washed with 3 CV of wash buffer, before the bound proteins were 
eluted with the appropriate buffer. In the case of GST fusion proteins, the elution 
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buffer contained 20 mM reduced glutathione, while 400 mM imidazole was used to 
elute 6xHis-MBP tagged proteins. Finally the column was washed and stored in 1 M 
NaCl containing 0.2% NaN3. Purified fractions were analysed by SDS-PAGE. 
 
2.11.4.3 Cleavage of recombinant protein  
GST fusion proteins were cleaved with recombinant 3C protease, while 6xHis-MBP 
fusion proteins were cleaved with Tev protease. Fusion proteins were pooled and 
transferred to a SnakeskinTM dialysis bag (Thermo Scientific) with a 3.5 kDa MWCO. 
After addition of the appropriate protease, the dialysis bag was placed in 2 litres of 
Cleavage Buffer and cleavage allowed to proceed overnight at 4 °C. Following 
cleavage, the fusion tag was removed by affinity chromatography.  
 
2.11.4.4 HiTrapTM Heparin affinity/ion exchange chromatography 
In some cases proteins were purified further using a HiTrapTM Heparin column (GE 
Healthcare). The heparin column has two modes of action: as an affinity ligand for 
growth factors and antithrombin III, and as a cation exchanger due to its high content 
of anionic sulphate groups. In this work the HiTrapTM Heparin column was primarily 
used as an ion exchanger. Protein samples were dialysed against Low Salt Buffer 
(50 mM Tris, pH 8.0, 50 mM NaCl and 20 mM -mercaptoethanol) and loaded onto 
the heparin column which was pre-equilibrated with 5 CV of Low Salt Buffer. The 
flow through was collected and the column washed with 3 CV of Low Salt Buffer. 
Bound proteins were eluted with buffer containing 1 M NaCl. Eluted fractions were 
analysed by SDS-PAGE. The target protein was immediately dialysed against the 
appropriate assay buffer, concentrated and stored at 4 °C. 
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2.11.4.5 Cation exchange chromatography 
HA-ubiquitin, which was expressed without an affinity tag, was purified using a 
combination of acidic precipitation and cation exchange chromatography. Glacial 
acetic acid was added to clarified lysate until it turned cloudy, at roughly pH 4.5. 
Precipitated protein was removed by centrifugation and the supernatant transferred 
to a dialysis bag. The protein solution was dialysed against 2 litres of sodium 
acetate, pH 4.5 for 2 days, with 2 buffer changes. Following the dialysis step, 
precipitated protein was removed by centrifugation and the soluble fraction was 
applied to a 3 ml self-packed gravity-flow POROSR S20 column. The column was 
pre-equilibrated with sodium acetate, pH 4.5, before loading the protein solution. The 
flow through was collected and the column washed with 5 column volumes of sodium 
acetate, pH 4.5. Bound proteins were eluted from the column using PBS containing 
an increasing gradient of NaCl. 
 
2.11.5 SDS-PAGE analysis of proteins 
Protein samples were separated on SDS-PAGE gels according to Laemmli’s method 
[113]. 12-16% separating gels were prepared from a 40% acrylamide: bis-acrylamide 
stock as follows: 1.286-2.1 ml distilled H2O, 1.5-2 ml 40% acrylamide: bis-
acrylamide, 1.31 ml 1.5 M Tris pH 8.8, 42 μl 10 % SDS, 20 μl 10% ammonium 
persulphate and 10 μl TEMED (N, N, N’, N’-tetramethylethylenediamine). 4% 
stacking gels, made from 1.268 ml distilled H2O, 0.2 ml 40% bis-acrylamide: 
acrylamide, 0.5 ml 0.5 M Tris pH 6.8,  20 μl APS and 10 μl TEMED, was poured on 
top of the separating gels to a depth of about 1.5 cm. 
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Protein samples were prepared by adding an equal volume of 2x SDS sample buffer 
to the samples. The samples were vortexed briefly and then boiled at 95 °C for 5 
minutes. 20 μl of each sample was loaded into each well, unless otherwise stated. 
Electrophoresis was carried out at constant voltage of 150V. Gels were incubated in 
Coomassie staining solution (40 % ethanol, 10% acetic acid, 0.1% Coomassie Blue 
R-250 (Sigma)) for 30 minutes on an orbital shaker, after which they were destained 
overnight in destaining solution (10% glacial acetic acid). 
 
2.11.6 Immunodetection of proteins 
Protein samples were subjected to SDS-PAGE as described in Section 2.11.5. 
Thereafter proteins were transferred to nitrocellulose or PVDF membranes using 25 
mM Tris, 0.2 M glycine and 20% methanol as transfer buffer. Following the transfer, 
the membranes were blocked with 5% milk in TBS-T (Tris buffered saline containing 
0.1% Tween 20) and then incubated with the appropriate primary and secondary 
antibodies for 1 hour each. Following three 5-minute washes with TBS-T, the 
membranes were incubated with SuperSignalR West Pico chemiluminescent 
substrate solution (Pierce Biotechnology), exposed to film and developed. 
 
2.11.7 Determination of protein concentration 
The concentrations of total proteins of cell lysates or purified proteins were 
determined by direct spectrophotometric analysis at a wavelength of 280 nm using a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). For pure proteins molar 
extinction coefficients and molecular weights were calculated based on the amino 
acid sequences using the PROTPARAM tool available on the World Wide Web 
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(http://au.expasy.org/tools/protparam.html). This web server relies on the method of 
Gill and von Hippel [114].  
 
2.11.8 Lyophilisation  
Purified protein samples were snap-frozen in liquid nitrogen and lyophilised overnight 
on a Virtis Sentry (Virtis Company Inc.) freeze-drier. Lyophilised samples were 
stored at 4 °C. 
 
2.11.9 NMR experiments and data processing 
1-D proton and 15N-HSQC experiments were carried out on a 600 MHz Varian Inova 
spectrometer (Varian, Inc.) equipped with a room temperature triple-resonance 
(HCN) probe. Lyophilised samples were re-dissolved in 600 µl deionised water, with 
7% deuterium oxide (D2O) added to act as a lock signal. 5 mm NMR tubes were 
used for all experiments. NMR experiments were performed at 25 °C, using 50 mM 
sodium phosphate, pH 8.0, 150 mM NaCl and 5 mM -mercaptoethanol as the NMR 
sample buffer. The buffer composition for the NMR experiments was chosen to 
mirror those used in the pull-down and immunoprecipitation assays. 15N-HSQC 
experiments were performed by collecting 1024 complex points in the 1H dimension 
and 254 complex points in the 15N dimension. Spectra were processed using 
NMRPipe [115], while NMRView [116] was used to visualise and analyse spectra. 
Spectra were referenced so that DSS (4, 4-dimethyl-4-silapentane-1-sulfonic acid) 
corresponded to 0 ppm in the 1H dimension.  
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2.11.10 Interaction assays 
GST pull-down assays were performed by expressing the GST-tagged bait proteins 
in E. coli. E. coli cell lysates containing GST-tagged bait proteins were clarified by 
centrifugation and the total cellular protein concentration estimated by measuring the 
absorbance at 280 nm. Untagged purified prey proteins were prepared as described 
above. Aliquots of GST-tagged bait proteins or GST only were mixed with the prey 
protein, 20 μl of a 20% glutathione agarose slurry and 500 μl Binding Buffer (50mM 
Tris, pH 8.0, 5% BSA, 20 μM ZnCl2, 200 mM NaCl, 20 mM β-mercaptoethanol, 0.5% 
Triton X-100) and were incubated for 1 hour at room temperature. Additional 
reactions were included from which the E. coli lysate was omitted completely to 
serve as negative controls. The beads were pelleted by centrifugation and washed 3 
times with 500 μl of Binding Buffer, followed by 2 washes with 0.5 M NaCl. Finally 
the beads were resuspended in 30 μl of SDS sample buffer, boiled for 5 minutes at 
95 °C and loaded onto an SDS-PAGE gel. Prey proteins were immunodetected with 
the appropriate antibodies. 
 
Co-immunoprecipitation assays were performed by mixing 100 g of each cell lysate 
containing the proteins of interest with 20 μl agarose-conjugated antibodies against 
one of the proteins of interest. 500 μl Binding Buffer (50mM Tris, pH 8.0, 5% BSA, 20 
μM ZnCl2, 200 mM NaCl, 20 mM β-mercaptoethanol, 0.5% Triton X-100) were added 
to each reaction, which were then incubated for 1 hour at room temperature. The 
agarose beads were washed three times with Binding Buffer, followed by two 
washes with 0.5 M NaCl. Finally the beads were resuspended in 30 μl sample buffer, 
boiled for 5 minutes at 95 °C and separated on 16% SDS-PAGE gels. Precipitated 
proteins were immunodetected with the appropriate antibodies. 
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 2.11.11 Ubiquitination assays 
Ubiquitination assays were setup using either HEK293T or HeLa cell lysates with 
purified recombinant proteins. Reaction mixtures were made up as listed in Table 
2.5. All reactions were performed using buffer containing 50 mM Tris, pH 8.0, 150 
mM NaCl, 200 μM ZnSO4, 5 mM DTT and 10% glycerol. Reaction mixtures were 
briefly vortexed, centrifuged and then incubated at 37 °C with shaking, for 4-16 
hours. Reactions were stopped by the addition of 2x SDS-PAGE sample buffer. The 
results of the ubiquitination assays were analysed by immunodetection using the 
appropriate antibodies. 
 
 
Reagent Experimental reaction Control reaction 
Cell lysate 50-100 μg 50-100 μg 
E1 400 nM 400 nM 
E2 2 μM 2 μM 
E3  20 μM - 
Substrate  20 μM 20 μM 
MG132 (proteasome 
inhibitor) 
1 mM 1 mM 
HA-Ubiquitin 1 mM 1 mM 
Mg-ATP 4 mM 4 mM 
Buffer To 50 μl To 50 μl 
 
 
 
 
Table 2.5 Reagents used in the in vitro ubiquitination assay 
 
 
 
 
 
51 
 
Chapter 3: Cloning, expression and purification of the RBBP6 
p53-binding and the p53 DNA binding domain proteins 
3.1 Introduction 
RBBP6 was originally isolated as a p53 binding protein and shown to co-
immunoprecipitate with both p53 and pRb [7]. In that study by Simons and co-
workers, full length p53 was shown to interact with a truncated form of murine 
RBBP6 which the authors called PACT, corresponding to the C-terminal 1583 amino 
acids of full length RBBP6. The region of RBBP6 interacting with p53 was poorly 
localised to a region spanning residues 1220-1562 of PACT, corresponding to 
residues 1428-1761 of RBBP6. The interaction was shown to interfere with the DNA 
binding ability of p53 and was abolished by mutations mapping to the DNA binding 
domain of p53. In a later study by Gao and Scott the p53 binding region of RBBP6 
was further localised to a 110 amino acid segment of P2P-R corresponding to 
residues 1380-1490 of human RBBP6 [9]. This region overlaps with a segment of 
RBBP6 whose overexpression was shown to induce camptothecin-induced 
apoptosis.    
 
We set out to define the regions of interaction between p53 and RBBP6 further and 
to identify the specific amino acids involved in the interaction. The region 1422-1726 
(denoted p53BDFL for “p53 binding domain full length”) was selected as the most 
likely binding site on RBBP6, since this corresponds to the region identified by 
Simons and co-workers [7]. To further refine the region of RBBP6 that interacts with 
p53, additional truncated fragments that span p53BDFL were generated. Figure 3.1 
shows the nucleotide sequence and mRNA translation of this region. The fact that 
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this region was shown to interfere with the DNA binding properties of p53 gave us 
confidence that it represented the biologically appropriate site. Since the interaction 
between p53 and RBBP6 was abolished by mutations in the core DNA binding 
domain of p53 (hereafter referred to as p53CD), we hypothesized that the p53CD is 
sufficient for the interaction with RBBP6. GST fusion proteins with p53BDFL and a 
number of fragments, p53BD1-4, as well as a 6xHis-MBP-p53CD fusion protein were 
bacterially expressed and the purified proteins used in affinity pull-down and 
immunoprecipitation assays. In addition, 15N-labelled p53BD and p53CD were 
produced for NMR-based interaction studies.     
 
3.2 Cloning of the RBBP6 p53-binding domain sequences 
Primer design 
Primers were designed to amplify the full length p53BD of RBBP6 (residues 1422-
1726) as well as the four smaller fragments depicted schematically in Figure 3.2. The 
sequences of the primers are shown in Table 3.1. The primer combinations used as 
well as the corresponding RBBP6 residues is shown in Table 3.2. Each fragment 
incorporated the hemagglutinin (HA) tag and a BamHI site at the N-terminus, and an 
XhoI restriction site at the C-terminus. 
 
PCR amplification of the p53BD fragments 
Total RNA was extracted from HEK293T cells as described in Section 2.8 and used 
to synthesize cDNA as described in Section 2.9. The cDNA was used as a template 
to amplify the p53BDFL of RBBP6 as described in Section 2.6.2. Table 3.2 lists the 
oligonucleotide primer combinations used to amplify the different fragments of 
p53BD. 
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Figure 3.1 DNA sequence and mRNA translation of the p53BD of RBBP6 The p53BD of RBBP6 comprises residues 
1422-1726 of RBBP6 isoform 1. The full-length p53BD coding sequence was cloned in-frame with the hemagglutinin tag into 
the expression vector pGEX-6P-2. In addition, overlapping fragments which span p53BD were also cloned into pGEX-6P-2. 
Oligonucleotide primer positions and sequences are highlighted. Primer combinations used to amplify the p53BD fragments 
are colour coded. More details regarding the colour coding scheme and the regions amplified are contained in Table 3.1 and 
Table 3.2. 
agcactcagccagagaaagagagtaatttggaccgtctgaatgaacaaggaaattttaaaagtctgtctcaatcttccaaagaggctagaacgtcagataaacatgattccactcgtgct 
 S  T  Q  P  E  K  E  S  N  L  D  R  L  N  E  Q  G  N  F  K  S  L  S  Q  S  S  K  E  A  R  T  S  D  K  H  D  S  T  R  A  
tcctcaaataaagacttcactcccaatagagacaaaaaaactgactatgacaccagagagtattcaagttccaaacgtagagatgaaaagaatgaattaacaagacgaaaagactctcct 
 S  S  N  K  D  F  T  P  N  R  D  K  K  T  D  Y  D  T  R  E  Y  S  S  S  K  R  R  D  E  K  N  E  L  T  R  R  K  D  S  P  
tctcggaataaagattctgcatctggacagaaaaataaaccaagggaagagagagatttgcctaaaaaaggaacaggagattccaaaaaaagtaattctagtccctcaagagacagaaaa 
 S  R  N  K  D  S  A  S  G  Q  K  N  K  P  R  E  E  R  D  L  P  K  K  G  T  G  D  S  K  K  S  N  S  S  P  S  R  D  R  K  
cctcatgatcacaaagccacttatgatactaaacggccaaatgaagagacaaaatctgtagataaaaatccttgtaaggatcgtgagaagcatgtattagaagcaaggaacaataaagag 
 P  H  D  H  K  A  T  Y  D  T  K  R  P  N  E  E  T  K  S  V  D  K  N  P  C  K  D  R  E  K  H  V  L  E  A  R  N  N  K  E  
tcaagtggcaataaactactttatatacttaacccaccagagacacaggttgaaaaagagcaaattactgggcaaattgacaagagtactgtcaagcctaaaccccagttaagtcattcc 
 S  S  G  N  K  L  L  Y  I  L  N  P  P  E  T  Q  V  E  K  E  Q  I  T  G  Q  I  D  K  S  T  V  K  P  K  P  Q  L  S  H  S  
tctagactttcctctgacttaactagagaaactgatgaagctgcttttgaaccagactataatgaaagtgacagtgaaagtaatgtttctgtaaaagaagaggaatcttcaggaaacatt 
 S  R  L  S  S  D  L  T  R  E  T  D  E  A  A  F  E  P  D  Y  N  E  S  D  S  E  S  N  V  S  V  K  E  E  E  S  S  G  N  I  
tctaaggacctgaaagataaaatagtggagaaagcaaaagagagcctggacacagcagcagttgtccaggtgggcataagcaggaatcagagccacagcagccccagcgtcagccccagc 
 S  K  D  L  K  D  K  I  V  E  K  A  K  E  S  L  D  T  A  A  V  V  Q  V  G  I  S  R  N  Q  S  H  S  S  P  S  V  S  P  S  
agaagccacagtccttctggaagccagacccgaagccacagtagcagtgccagctcagca gaaagtcaggacagc 
 R  S  H  S  P  S  G  S  Q  T  R  S  H  S  S  S  A  S  S  A  E  S  Q  D  S 
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Figure 3.2 Fragments of the p53 binding domain used in this study Human RBBP6 
contains the highly conserved N-terminal ubiquitin-like domain, called DWNN, zinc and 
RING finger domains, a putative pRb-binding domain and the p53-binding domain. The 
regions corresponding to the p53BD fragments described in this thesis are indicated. 
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Primer name 
Sequence 
HAp53BD-F1 5’- CCC CTG GGA TCC TAC CCA TAC GAT GTT CCA GAT TAC 
GCT AGC ACT CAG CCA GAG -3’ 
HAp53BD-F2 5’- CCC CTG GGA TCC TAC CCA TAC GAT GTT CCA GAT TAC 
GCT ACT TAT GAT ACT AAA CGG-3’ 
HAp53BD-F3 5’- CCC CTG GGA TCC TAC CCA TAC GAT GTT CCA GAT TAC 
GCT GAA TCT TCA GGA AAC ATT-3’ 
HAp53BD-R1 5’- CG GCC CTC GAG TCA TCA AGA TTT TGT CTC TTC ATT -3’ 
HAp53BD-R2 5’- CG GCC CTC GAG TCA TCA TTT ATC TTT CAG GTC CTT -3’ 
HAp53BD-R3 5’- GAG GCG CTC GAG TTA TCA GCT GTC CTG ACT TTC TGC 
TGA GCT -3’ 
HA-F 5'-GAT CCT ACC CAT ACG ATG TTC CTG ACT ATG CGG GC-3' 
HA-R 5'-TCG AGC CCG CAT AGT CAG GAA CAT CGT ATG GGT AG-3' 
Table 3.1 Oligonucleotides used for the amplification of p53BD fragments. 
Restriction enzyme recognition sites are underlined. The HA tag sequence is shown 
in red. 
 
 
Primer combination Fragment name Amplicon size RBBP6 residues 
HAp53BD-F1/ HAp53BD-R1 HAp53BDFL 966 bp 1422-1726 
HAp53BD-F1/ HAp53BD-R2 HAp53BD1 468 bp 1422-1560 
HAp53BD-F2/ HAp53BD-R3 HAp53BD2 414 bp 1548-1668 
HAp53BD-F3/HAp53BD-R1 HAp53BD3 264 bp 1656-1726 
HAp53BD-F1/ HAp53BD-R3 HAp53BD4 792 bp 1422-1668 
Table 3.2 Oligonucleotide combinations used to amplify the various p53BD 
fragments. 
 
PCR products were resolved on a 0.8% agarose gel as described in Section 2.6.6. 
Lane 2 in Figure 3.3(A) shows an amplicon of about 970 bp, the expected size for 
the p53BDFL fragment. The PCR fragment was purified with a GFX DNA purification 
kit (GE Healthcare), digested with BamHI and XhoI and cloned into the BamHI and 
XhoI sites of pGEX-6P-2.  
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M     1       2     3     4    5     6     7     8     9 
 M: Mw marker 
  1: Negative control 
  2: p53BDFL amplicon  
1031 bp 
Figure 3.3 Cloning of the p53BDFL sequence into pGEX-6P-2 (A) The p53BD 
full-length fragment was amplified from HEK293T cDNA. Lane 2 shows an 
amplicon of approximately 970 bp, the expected size of the p53BDFL fragment. 
The fragment was digested with BamHI and XhoI and cloned into pGEX-6P-2. 
(B) Plasmid DNA was isolated and screened for p53BDFL inserts by digestion 
with BamHI and XhoI. Lane 1 shows undigested pGEX-6P-2 plasmid DNA, while 
lanes 2-9 show digested DNA from the presumptive positive clones. Clones 3-5, 
7 and 9 are positive for p53BDFL inserts (~970 bp). 
  M: Mw marker 
   1: Undigested plasmid DNA 
2-9: Plasmid DNA digested with 
Bam HI and XhoI 
1031 bp 
B 
M        1         2  A 
900 bp 
900 bp 
1500 bp 
1500 bp 
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Plasmid DNA was isolated from positive transformants and digested with BamHI and 
XhoI to screen for the release of p53BDFL inserts, as shown in Figure 3.3(B). Lanes 
3-5, 7 and 9 contain inserts of the expected size (~ 970 bp). The sequence identity of 
positive clones was confirmed by DNA sequencing. 
  
The isolated HA tag was also cloned into pGEX-6P-2 to serve as a negative control 
for interaction assays using GST-HA-p53BD proteins. Complementary 
oligonucleotides coding for the HA tag (HA-F and HA-R in Table 3.1) were designed 
so that when annealed they would produce a double-stranded linker fragment with 
“sticky ends” which could be cloned directly into the BamHI and XhoI sites of pGEX-
6P-2. The HA-containing linker was successfully cloned and the sequence confirmed 
by DNA sequencing. 
 
The pGEX-6P-2-p53BDFL plasmid DNA was subsequently used as a template to 
amplify overlapping fragments p53BD1, p53BD2, p53BD3 and p53BD4 depicted 
schematically in Figure 3.2. Lanes 3-5 in Figure 3.4(A) and lane 2 in Figure 3.4(B) 
show amplicons of the expected sizes.  The PCR products were purified, digested 
with BamHI and XhoI and cloned into pGEX-6P-2. A restriction digestion with BamHI 
and XhoI released fragments of the correct sizes (see Figure 3.5): 450 bp in lanes 2-
4 corresponding to p53BD1, 400 bp in lanes 5-7 corresponding to p53BD2, 255 in 
lanes 8-10 bp corresponding to p53BD3 and 770 bp in lanes 11-13 corresponding to 
p53BD4. All sequences were directly verified by DNA sequencing. 
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Figure 3.4 PCR amplification of the p53BD1-4 fragments p53BD fragments were amplified from the pGEX-HA-
p53BDFL construct. Lanes 2, 3 and 4 in A shows amplicons for p53BD1-3 respectively while lane 2 in B shows the 
p53BD4 amplicon. The expected sizes of the various amplicons were 468bp (lane 3), 414 bp (lane 4), 264 bp (lane 5) 
and 792 bp (lane 2 in B). Lane 2 in A shows the p53BDFL amplicon as a reference size. Lanes 1 in A and B show the 
negative controls with no template added. 
    M   1   2    3    4    5                                                                        M     1       2 
1031 bp 
500 bp p53BD4 amplicon 
p53BDFL amplicon 
p53BD1 amplicon 
p53BD2 amplicon 
p53BD3 amplicon 
A B 
500 bp 
1031 bp 
700 bp 
800 bp 
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Figure 3.5 Screening for p53BD1-4 inserts Putative positive colonies were picked and used to inoculate 10 ml of LB containing 100 
mg/ml ampicillin and grown overnight. Plasmid DNA was isolated and digested with Bam HI and XhoI to release p53BD inserts. Lane 
1 shows pGEX-6P-2 digested with BamHI and XhoI, while lanes 2-13 show digested DNA from the various clones. All clones, except 
in lane 13 are positive for the various p53BD inserts; 450 bp in lanes 2- 4 for p53BD1, 400 bp corresponding to p53BD2 in lanes 5-7, 
255 bp corresponding to p53BD3 in lanes 8-10 and about 780 bp for p53BD4 in lanes 11 and 12.   
    M    1   2    3   4         5    6    7        8    9  10  M  11  12 13 
     M: Mw marker 
 1-13: Putative positive clone DNA digested with BamHI and XhoI 
1031 bp 
500 bp 
    
p53BD1  p53BD2  p53BD3  p53BD4  
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3.3 Bacterial expression of p53BD and p53CD proteins 
3.3.1 Expression and purification of p53BD proteins 
Clarified bacterial lysates containing GST-HA-p53BD1-4 fusion proteins were western 
blotted to confirm that the proteins had been expressed and that the HA tag was 
detectable using an anti-HA probe. The expected sizes of the various fusion proteins 
were 43.5 kDa for GST-HA-p53BD1, 41.20 kDa for GST-HA-p53BD2, 34 kDa for 
GST-HA-p53BD3 and 55.65 kDa for GST-HA-p53BD4. GST-HA-p53BD proteins were 
immunodetected using an HRP conjugated anti-HA antibody (Santa Cruz 
Biotechnology) at a dilution of 1:1000. Figure 3.6 shows that the antibody detected 
the GST-p53BD fusion proteins in lanes 2-5, but not the control lysate in lane 1 
containing only GST. The anti-HA antibody also showed cross-reactivity with an 
unknown bacterial protein, indicated by the red arrow. This protein, migrating at 
roughly 70 kDa is detected in all lanes, even lane 1, where no HA-tagged protein 
was loaded. Significant amounts of degradation products were also detected, 
appearing as lower molecular weight bands in Figure 3.6, suggesting that the 
truncated fragments are unstable and sensitive to proteolysis. 
 
GST-HA-p53BD4 fusion protein was subsequently produced on a larger scale and 
purified. Figure 3.7 shows the result of the different purification steps. GST-HA-
p53BD4 fusion protein (lane 2) was purified from the clarified cell lysate (lane 1) 
using a glutathione agarose column and cleaved using 3C protease (lane 3). GST 
was removed using a heparin column to which the HA-p53BD4 (lane 7) bound but 
GST did not (lane 5). 
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M      1       2       3      4      5 
M: Molecular weight 
marker 
1: GST only lysate 
2: GST-p53BD1 lysate 
3: GST-p53BD2 lysate 
4: GST-p53BD3 lysate 
5: GST-p53BD4 lysate 
Figure 3.6 Immunodetection of GST-p53BD1-4 with an anti-HA antibody E. coli 
BL21(DE)pLysS cultures expressing the various GST-HAp53BD fusion proteins 
were lysed and the lysates clarified. 10 μg of total cellular protein was 
electrophoresed and transferred to a nitrocellulose membrane and probed with an 
anti-HA antibody. The antibody detected the GST-HA tagged p53BD proteins 
(lanes 2-5) but not GST alone in lane 1.  
An unknown bacterial protein migrating at roughly 70 kDa, indicated by the red 
arrow, is also detected by the anti-HA antibody. 
116 kDa 
25 kDa 
34 kDa 
43 kDa 
55 kDa 
72 kDa 
95 kDa 
18.4 kDa 
Unknown bacterial protein 
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Figure 3.7 Purification of p53BD4 GST-p53BD4 fusion protein (lane 2) was purified from 
the clarified E. coli BL21(DE) pLysS lysate (lane 1) using a glutathione agarose column and 
cleaved with 3C protease (lane 3). p53BD4 was separated from the GST tag by passage 
through a glutathione agarose column protein (lane 4), followed by a final purification step 
using a HiTrapTM Heparin column. GST does not bind to the heparin column and appears in 
the flow through (lane 5), while p53BD4 is retained by the heparin column and appears in the 
elution fraction (lane 7). 
116 kDa 
35 kDa 
25 kDa 
18.4 kDa 
14.4 kDa 
66.2 kDa 
45 kDa 
M     1        2       3       4       5      6       7 
    M: Mw marker 
     1: Clarified lysate 
     2: Purified GST-p53BD4 fusion protein 
 3-4: 3C protease cleavage products 
    5: HiTrapTM Heparin column flow through 
    6: HiTrapTM Heparin column wash 
    7: HiTrapTM Heparin column elute 
p53BD4 
GST 
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3.3.2 Characterisation of p53BD4 by mass spectrometry  
Although the predicted molecular weight of p53BD4 is approximately 29.6 kDa, on 
SDS-PAGE gels the protein migrated with an apparent molecular weight of 40 kDa, 
with a putative major degradation product of 25 kDa. The two species were partially 
separated using size exclusion chromatography (Figure 3.8) and analysed by mass 
spectrometry. 
 
Mass spectrometry analysis, represented by Figures 3.9(A) and (B), revealed that 
the two proteins have molecular weights of 26.77 kDa and 29.96 kDa respectively. 
The protein with a molecular weight of 29.96 kDa migrates at an apparent molecular 
weight of about 40 kDa. This atypical migration on SDS-PAGE gels, together with an 
increased susceptibility to proteolytic degradation (also evident for p53BD4 from 
Figures 3.7, 3.8 and the mass spectrograms) is characteristic of intrinsically unfolded 
proteins [117, 118]. Intrinsically unfolded proteins (IUPs) are either unstructured 
across their entire length or contain large stretches of 50 or more amino acids that 
lack a defined tertiary structure. While most IUPs undergo binding-induced folding, 
some, like the cytoplasmic region of the T cell receptor zeta subunit, bind their 
partners in an extended conformation [119, 120].  Prediction servers such as RONN 
(http://www.strubi.ox.ac.uk/RONN) and the Swiss Model module of the Expasy 
server (http://swissmodel.expasy.org/) were used to analyse the p53BD4 amino acid 
sequence and to predict whether or not the domain is folded. Figure 3.10, showing 
the result from the Swiss Model server, indicate that p53BD4 is unfolded across 
almost its entire length. Unfolded regions are indicated by asterisks below the 
particular amino acid residues. Similar results were obtained from RONN and other 
servers. 
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M    1          2          3      4       5        6        7 
M: Molecular weight marker 
1: Concentrated p53BD4 
2-7: Elution fractions 
Figure 3.8 Gel filtration of concentrated p53BD4 Concentrated p53BD4 (lane 1) showed 
two major bands of approximately 40 kDa and 25 kDa, along with other smaller 
degradation products. These proteins were separated on a Sephacryl S100 gel filtration 
column (Amersham Pharmacia Biotech). Lanes 2-7 shows fractions taken from different 
elution peaks.  Fractions corresponding to the two major protein bands (40 and 25 kDa, 
respectively) were pooled, concentrated and subjected to MALDI-TOF mass spectrometry 
to accurately determine the sizes of the two proteins.  
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A 
B 
Figure 3.9 Mass spectrograms of purified p53BD4 Depicted in (A) is a mass 
spectrogram of purified 15N-labelled p53BD4 showing a major peak at 29967 Da which 
corresponds to the expected size of the protein based on the amino acid sequence. 
Depicted in (B) is a mass spectrogram showing a major peak at 26773 Da 
corresponding to the major degradation product of p53BD4 that is visible on SDS-PAGE. 
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Figure 3.10 Secondary structure and disorder prediction for p53BD4 
The disorder prediction was carried out using the Swiss Model server 
(http://swissmodel.expasy.org/). The server predicted that the domain contains 
extensive regions that are disordered (indicated by asterisks below amino acids).  
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3.3.3 Characterisation of p53BD4 by NMR 
The 15N-HSQC experiment correlates the 15N chemical shift of the backbone 
nitrogen with the 1H shift of the directly attached proton for every amino acid residue 
in a protein. The correlation is reflected as a cross-peak for every residue in the 
resulting spectrum. The position of the cross-peaks is dependent on the chemical 
environment of each amide in the protein, resulting in a unique fingerprint pattern of 
cross-peaks for every protein. Therefore the 15N-HSQC spectrum is regarded as a 
signature spectrum in protein NMR because it easily distinguishes one protein from 
another. Folded proteins have well-dispersed spectra whereas unfolded proteins 
have spectra in which the amide proton resonances cluster around a value of 8.3 
ppm.  
 
Figures 3.11(A) and (B) depict the 15N-HSQC spectra of the 26.77 kDa and 29.96 
kDa species respectively. The lack of chemical shift dispersion seen in the 15N-
HSQC spectra of p53BD4 clearly indicates that both are unfolded. Furthermore the 
two spectra are highly similar, confirming that the 26.77 kDa species is a degradation 
product of the 29.96 kDa form, which corresponds to the full length p53BD4.  
 
3.4 Expression and purification of p53CD 
3.4.1 Expression of p53CD 
The p53CD expression construct, pETM41-p53CD, was a kind gift from Dr. 
Sebastian Charbonnier, École Supérieure de Biotechnologie de Strasbourg, 
Strasbourg, France. Residues 94-311 of human p53, corresponding to the DNA 
binding domain, was expressed as an N-terminal 6xHis-tagged fusion in tandem with 
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Figure 3.11 15N-HSQC spectra of p53BD4 The spectra in (A) and (B) correspond to the 26.77 kDa and 29.96 kDa species 
respectively. The spectra are highly similar, confirming that the 26.77 kDa form corresponds to a degradation product. The 
spectra show very little dispersion, indicating that both species are unfolded. 
B A 
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maltose binding protein (MBP) as described in Section 2.11.4.2. The 6xHis-tag was 
utilized as an aid in purification of the fusion protein while the MBP tag provided 
enhanced solubility [121, 122]. The amino acid sequence of the expressed p53CD 
protein can be found in Appendix I. The expected molecular weight of the fusion 
protein is 68.343 kDa. The fusion protein included a Tev (tobacco etch virus) 
protease site facilitating removal of the MBP to produce a protein with an expected 
molecular weight of 24.766 kDa.  
 
The 6xHis-MBP-p53CD fusion protein was purified out of bacterial lysate using 
immobilised metal affinity chromatography (IMAC), yielding a strong band migrating 
at approximately 70 kDa on SDS-PAGE (Figure 3.12(A), lanes 4-5). Following 
cleavage with Tev protease the 6xHis-MBP fusion tag was removed by retaining 
p53CD on a heparin affinity column (Figure 3.12(B), lane 4).  
 
3.4.2 Characterisation of p53CD by mass spectrometry  
The concentrations of purified p53CD samples were determined by measuring the 
absorbance at 280 nm and using the published molar extinction coefficient of 15930 
M-1 cm-1 [123]. Sample concentrations varied from 0.2-0.4 mM. Purified samples 
were analysed by mass spectrometry to assess the extent of isotope labelling.  
Figure 3.13 depicts a mass spectrum obtained for 15N-p53CD, showing a major peak 
at 25082 Da. The expected mass of the wild-type protein, as determined using the 
Protein Parameter tool of the Expasy server (www.expasy.org), is 24 766 Da. Since 
the protein contains 324 nitrogen atoms, replacement of all 14N by 15N would yield a 
mass of 247 66 + 324 = 25090 Da. The observed mass of 25 082 Da therefore 
indicates greater than 97 % labelling of p53CD with 15N.   
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Figure 3.12 Purification of p53CD (A) 6xHis-MBP-p53CD fusion protein was 
purified using a nickel sepharose column. Lanes 4 and 5 shows a band of 
approximately 70 kDa, corresponding to the expected size of the 6xHisMBP-p53CD 
fusion protein. The purified fusion protein was cleaved with recombinant Tev 
protease. (B) Following cleavage p53CD was purified away from the 6xHisMBP 
fusion tag using a HiTrapTM Heparin affinity column. The flow through and wash 
fractions (lanes 2 and 3) contained the 6xHis-MBP fusion tag, while p53CD bound to 
the column and appears in the elution fraction (lane 4).  
 
 M: Mw marker 
  1: Clarified cell lysate 
  2: Flow through 
  3: Wash 
  4-5: Elution fractions 
35 kDa 
116 kDa 
14.4 kDa 
25 kDa 
18.4 kDa 
66.2 kDa 
 45 kDa 
6xHis-MBP-p53CD 
 M: Mw marker 
  1: Partially purified p53CD 
  2: Flow through 
  3: Wash fraction 
  4: Elute 
14.4 kDa 
25 kDa 
18.4 kDa 
66.2 kDa 
 45 kDa 
 35 kDa 
p53CD 
6xHis-MBP 
B 
A 
116 kDa 
M          1               2              3              
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Figure 3.13 Mass spectrogram of purified 15N-p53CD The spectrogram shows a major 
peak at 25082 Da, which corresponds well to the expected size of the p53CD. The 
expected size of fully 15N- labelled p53CD is 25090 Da. The observed size of 25082 Da 
thus indicates > 97 % incorporation of 15N atoms into the domain. 
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3.4.3 Characterisation of p53CD by NMR  
15N-HSQC NMR spectra of the p53CD were obtained as described in Section 2.11.8 
(see Figure 3.14(A)). The spectrum shows good resonance dispersion in both the 
15N dimension and the proton dimension, indicating that the protein is folded. The 
spectrum is also highly similar to the spectrum (Figure 3.14(B)) reported by Wong 
and co-workers [4], confirming that the protein we expressed was indeed the core 
domain of p53. Since the spectrum in Figure 3.14(B) has been assigned no attempt 
was made to assign the spectrum shown in Figure 3.14(A). 
 
3.5 Site directed mutagenesis of p53CD 
The R270C mutation of the core domain of p53 abolished the interaction between 
murine p53 and PACT [7]. The sequence alignment shown in Figure 3.15 shows that 
R273 is the human equivalent of R270 in mice. The R273H mutation is one of the 
most important p53 mutations, since it eliminates an essential DNA contact residue 
[124]. Thus the mutant p53CD-R273H was generated to characterise the effect of 
this mutation on the p53CD-RBBP6 interaction in humans. The mutation was 
generated using the PhusionTM Site Directed Mutagenesis kit (Finnzymes), in which 
adjacent primers amply in different directions, producing a linear copy of the entire 
template. The linear fragments are then blunt-end ligated to produce circular DNA 
and transformed. Mutations are introduced by incorporating the desired nucleotide 
changes into the primers. Table 3.3 lists the oligonucleotide primers used to 
generate the pETM-41-p53CD-R273H construct, with the mutant codon CAT 
indicated in red. The primers were designed based on the sequence of wild-type 
p53CD. Details of the procedure are given in Section 2.11. 
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Figure 3.14 15N-HSQC spectra of the p53 Core Domain (A) 15N-HSQC spectrum of the p53CD was acquired at 25°C on a 600 
MHz spectrometer. The spectrum shows good dispersion of resonances, in both the 1H and 15N dimensions, indicative of a 
folded protein. The spectrum is in good agreement with the assigned 15N-HSQC spectrum of p53CD (B) reported by Wong and 
co-workers [4]; thus no attempt was made to assign the spectrum in (A). 
A B 
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CLUSTAL 2.0.12 multiple sequence alignment 
 
Hsp53           ---MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTED 57 
Mmusp53         MTAMEESQSDISLELPLSQETFSGLWKLLPPEDILP--SPHCMDDLLL-PQDVEEFFE-- 55 
                   ***.*** *:* ********.****** :::*.  ..:.****:* *:*:*::*    
Hsp53           PGPDEAPRMPEAAPRVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSG 117 
Mmusp53         -GPSEALRVSGAPAAQDPVTETPGPVAPAPATPWPLSSFVPSQKTYQGNYGFHLGFLQSG 114 
                 **.** *:. *..   *.. :* *.*****..***** *********.***:****:** 
Hsp53           TAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCP 177 
Mmusp53         TAKSVMCTYSPPLNKLFFQLAKTCPVQLWVSATPPAGSRVRAMAIYKKSQHMTEVVRRCP 174 
                ***** *****.***:* ************.:***.*:*********:************ 
Hsp53           HHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYM 237 
Mmusp53         HHERCSDGDGLAPPQHLIRVEGNLYPEYLEDRQTFRHSVVVPYEPPEAGSEYTTIHYKYM 234 
                *******.****************  ***:**:**************.**: *****:** 
Hsp53           CNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHH 297 
Mmusp53         CNSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENFRKKEVLCP 294 
                ******************************:********************:***      
Hsp53           ELPPGSTKRALSNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAAQAGK 357 
Mmusp53         ELPPGSAKRALPTCTSASPPQKKKPLDGEYFTLKIRGRKRFEMFRELNEALELKDAAHATE 354 
                ******:****.. **:**  ************:****:*****************:* : 
Hsp53           EPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD 393 
Mmusp53         ESGDSRAHSSLQP--------RAFQALIKEESPNC- 381 
                *.*.******           *  : ::* *.*:.  
Figure 3.15 Sequence alignment of human and mouse p53 core domains The mouse 
and human p53CD amino acid sequences were aligned using ClustalW [2]. R273 (human) 
and R270 (mouse) highlighted in red are aligned, indicating that the two residues are 
equivalent in mouse and human p53 respectively. 
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Table 3.3 Oligonucleotide primers used to generate the pETM-41-p53CD-R273H mutant 
construct. 
 
 
PCR amplification of the pETM-41-p53CD to incorporate the desired mutation is 
shown in Figure 3.16(A). Direct DNA sequencing confirmed that the mutation had 
been successfully incorporated. The mutant protein was expressed as described in 
Section 2.11.1 and immunodetected with an antibody against full-length wild-type 
human p53 as described in Section 2.11.10. Figure 3.16(B) depicts the results of the 
immunodetection of both the wild-type 6xHis-MBP-p53CD and the 6xHis-MBP-
p53CD-R273H mutant fusion proteins by an anti-p53 antibody. Both the wild-type 
protein (lane 2) and the 6xHis-MBP-p53CD-R273H mutant (lane 1) proteins were 
detected. 
 
3.5 Investigation of the interaction between p53CD and p53BD 
3.5.1 Chemical shift perturbation analysis of the p53CD/p53BDFL 
interaction 
A 0.3 mM 100% 15N-enriched sample of the human p53CD was produced as 
described above and used to investigate the interaction with unlabelled full length 
p53BD. A 15N-HSQC spectrum was first recorded, which produced a spectrum 
similar to that shown in Figure 3.14(A). Since the p53CD was found to be stable for 
only a few hours at NMR concentrations, a single aliquot of p53BDFL was added to a  
Primer name Sequence 
R273H 1 5’ TTTGAGGTGCATGTTTGTGCC 3’ 
R273H 2 5’GCTGTTCCGTCCCAGTAGATTACC 3’  
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M     1         2          3        
pETM-41-p53CD-R273H amplicon        
pUC19 control plasmid amplicon         
1031 bp 
1500 bp 
2000 bp 
2500 bp 
5000 bp 
Figure 3.16 Generation and immunodetection of the p53CD-R273H 
mutant A. The pETM-41-p53CD expression construct was used as a template 
to amplify the pETM-41-p53CD-R273H mutant amplicon. Lane 1 shows the 
negative control (no template DNA), lane 2 shows amplification of the pUC19 
control plasmid while lane 3 shows the amplification of pETM-41-p53CD-
R273H mutant plasmid. B. 6xHis-MBP-p53CD (lane 1) and 6xHis-MBP-
p53CD-R273H (lane 2) were western blotted and detected with anti-p53 
antibody. Both proteins were successfully detected at ~72 kDa. The lower 
bands at approximately 25 kDa correspond to proteolytic cleavage of the 
fusion proteins. 
M: Molecular weight marker 
 1: 6xHisMBP-p53CD-R273H lysate 
 2: 6xHisMBP-p53CD wild-type lysate 
   M        1         2 
6xHis-MBP-p53CD and 6xHis-MBP-p53CD-R273H 
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final concentration of 0.4 mM, representing a 1.3-fold excess over p53CD, and a 15N-
HSQC spectrum recorded under identical conditions. Most surprisingly, when the two 
spectra were overlaid no differences were observable between the two (data not 
shown). 
 
3.5.2 GST pull-down assay using full length p53BD and p53CD 
Due to the negative result obtained above, it was decided to repeat the same assay 
used in the original report by Simons and co-workers [7], but using p53CD rather 
than full length p53. E. coli cell lysates containing overexpressed GST-HA-p53BDFL 
or GST-HA were incubated with purified p53CD and agarose beads conjugated to 
glutathione as described in Section 2.11.10. After extensive washing, proteins 
retained by the glutathione agarose were subjected to western blot analysis, 
detected using a polyclonal antibody against full length p53 (Santa Cruz) (Figure 
3.17). GST-HA-p53BDFL was able to pull down p53CD (lane 3) but GST-HA was not 
(lane 2) and neither were the glutathione agarose beads (lane 1). In addition to 
p53CD itself, residual amounts of un-cleaved 6xHis-MBP-p53CD fusion protein are 
also pulled down by the p53BDFL (lane 3), as well as a degradation product of around 
20 kDa. This result confirms for the first time that the interaction between p53 and 
RBBP6 involves the DNA Binding Domain of p53. 
 
3.5.3 Localization of the interaction within the p53BD 
In order to further localise the region of the p53BD responsible for binding to the 
p53CD, the GST pull-down assay was repeated using the truncated fragments 
shown schematically in Figure 3.2. The results are shown in Figure 3.18. GST-HA- 
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Figure 3.17 Immunodetection of p53CD precipitated by GST-HAp53BDFL GST-
HAp53BDFL is able to pull down p53CD (lane 3), whereas GST-HA alone is not (lane 
2). Minimal binding of p53CD to GST-HA occurred as evidenced by the feint bands 
visible in lane 2. In contrast, a strong signal is visible in lane 3 indicating that specific 
binding occurred between p53CD and GST-HAp53BDFL. p53CD did not bind to the 
beads (lane 1). 
 M: Mw marker 
  1:  p53CD + beads 
  2:  p53CD + GST-HA  
  3: p53CD + GST-HAp53BDFL  
p53CD 
M    1       2         3 
43 kDa 
72 kDa 
55 kDa 
26 kDa 
17 kDa 
11 kDa 
34 kDa 
95 kDa 
6xHisMBP-p53CD 
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p53BD4 was able to pull down p53CD (lane 5), while none of the other fragments 
were able to, nor was GST-HA alone (lanes 1-4). Surprisingly p53BD1, which 
corresponds to the region defined by Gao and Scott as the p53 interaction region of 
murine RBBP6, did not interact with p53 in this assay, while GST-HA-p53BD4, which 
spans GST-HA-p53BD1 and GST-HA-p53BD2, did. None of the three smaller 
fragments was able to pull-down p53CD. This would appear to suggest that GST-
HA-p53BD4 adopts a folded structure that is not able to form when the domain is 
divided into two separate parts. However this conclusion is inconsistent with the 
NMR data presented in Figure 3.11 which shows p53BD4 to be unfolded. 
 
3.5.4 Co-immunoprecipitation of recombinant GST-HA-p53BD4 by 
endogenous human p53  
To confirm the interaction between p53 and p53BD4 of RBBP6, a co-
immunoprecipitation assay was carried out using endogenous p53 in HEK293T cell 
lysate and E. coli lysates containing overexpressed GST-HA-p53BD4 or GST-HA. 
P53 was precipitated using an agarose-conjugated antibody against full length p53 
(Santa Cruz) and co-precipitated HA-p53BD4 were detected using an anti-HA 
antibody. The results are presented in Figure 3.19. As expected, anti-p53 was able 
to precipitate GST-HA-p53BD4 in the presence of HEK293T lysate containing 
endogenous p53 (lane 3), but not in the absence of HEK293T lysate (lane 2). In the 
presence of HEK293T lysate anti-p53 was not able to precipitate GST-HA (lane 1) 
even though it was able to precipitate GST-HA-p53BD4. Hence both p53BD4 and p53 
are required for the interaction to take place. 
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Figure 3.18 Immunodetection of p53CD precipitated by GST-HAp53BD1-4 
GST-HAp53BD4 was able to pull down p53CD (lane 5) but GST-HAp53BD1-3 was 
not (lanes 2-4). 2 μg of purified p53CD was incubated with 40 μg of cell lysates 
containing GST-HA and the truncated GST-HAp53BD proteins. The proteins were 
incubated with glutathione agarose beads in binding buffer for an hour and then 
washed extensively with binding buffer, followed by 2 washes with 0.5 M NaCl. 
Precipitated p53 core domain was detected with a polyclonal antibody raised 
against full-length p53. Lane 6 shows purified p53CD, used as a blotting control 
and size marker. 
p53CD 
M   1       2       3       4      5     6 
  M: Mw marker 
   1: p53CD + GST-HA 
  2: p53CD + GST-HAp53BD1 
  3: p53CD + GST-HAp53BD2 
  4: p53CD + GST-HAp53BD3 
  5: p53CD + GST-HAp53BD4 
  6:p53CD 
55 kDa 
26 kDa 
17 kDa 
11 kDa 
34 kDa 
43 kDa 
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Figure 3.19 Immunodetection of HA-p53BD4 precipitated by endogenous p53 
Antibodies against p53 were able to precipitate bacterially expressed GST-HA-
p53BD4 (lane 3) in the presence of HEK293T cell lysate containing endogenous p53, 
but not in the absence of HEK293T lysate (lane 2). Antibodies against p53 were not 
able to precipitate GST-HA even in the presence of endogenous p53 (lane 1). 100 μg 
of E. coli lysates containing either GST-HA or GST-HA-p53BD4 was mixed with 100 
μg of a HEK293T cell lysate and incubated with agarose conjugated anti-p53 
antibodies. While minimal precipitation of the GST-HAp53BD4 by the anti-p53 
antibodies alone occurred (lane 2), endogenous p53 clearly interacts with GST-
HAp53BD4, as evidenced by the strong signal corresponding to GST-HAp53BD4 in 
lane 3. The GST-HA-p53BD4 fusion protein was detected with an anti-Ha probe. 
 M: Mw marker 
  1: GST-HA lysate + HEK293T lysate  
  2: GST-HA-p53BD4 lysate  
  3: GST-HA-p53BD4 lysate + HEK293T lysate  
     1          2        3       
GST-HA-p53BD4 
72 kDa
55 kDa 
43 kDa 
34 kDa 
26 kDa 
17 kDa 
11 kDa 
95 kDa  
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The top most band appearing in lanes 1 and 3 is present even when p53BD4 is not 
present (lane 1) and so can be ignored. The two feint bands in lane 2 suggest that 
there is some non-specific binding of HA-p53BD4 to the anti-p53-conjugated beads 
which could have been removed with more stringent washing. However the signal in 
lane 3 is well above background. 
 
3.5.5 Effect of DNA Binding Domain mutations 
Simons and co-workers reported that the R270C mutation in mouse abolished the 
interaction between p53 and PACT. GST pull-down assays using GST-HAp53BD4 
and p53CD-R273H were performed as described for p53CD wt above, to evaluate 
the effect of the mutation on p53CD binding to p53BD4. 
 
The p53CD-R273H mutation failed to inhibit the binding of p53CD to p53BD4 (data 
not shown). This could be due to the amino acid substitution chosen for this analysis. 
In this study arginine, a basic residue was substituted with another basic residue, 
histidine. In the original report by Simons and co-workers arginine was mutated to a 
cysteine, a neutral residue. 
 
3.5.6 Chemical shift perturbation analysis of the p53BD4/p53CD 
interaction 
Previous attempts to find evidence for an interaction by observation of the 15N-HSQC 
of 15N-labelled p53CD on addition of unlabelled full length p53BD failed to identify 
any chemical shift changes. A possible explanation for this failure was that the 
magnitudes of the chemical shifts experienced by p53CD were too small to be 
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observable. On the other hand, p53BD4 was found to be unfolded, with a poorly-
dispersed 15N-HSQC spectrum. If the domain folded on interaction with the p53CD 
domain, it should be accompanied by large chemical shift changes in the 15N-HSQC 
of p53BD4.  
 
Following localisation of the interaction to the region of p53BD4, it was decided to 
repeat the investigation by observing the effect of unlabelled p53CD on the 15N-
HSQC of 15N-labelled p53BD4, as well as the effect of unlabelled p53BD4 on the 15N-
HSQC of 15N-labelled p53CD. 15N-labelled and unlabelled p53BD4 and p53CD 
samples were prepared as described above. A 15N-HSQC spectrum was recorded 
using a 0.4 mM sample of 15N-p53CD under the conditions described in Section 
2.11.8. 300 l of a 1.5 mM unlabelled p53BD4 sample was added, producing a final 
p53BD4 concentration of 0.62 mM and a final p53CD concentration of 0.2 mM after 
which the 15N-HSQC spectrum of p53CD was recorded again. An overlay of the two 
spectra is shown in Figure 3.20 As before there are no significant differences 
between the two spectra. 
 
Next, the 15N-HSQC spectrum of a 0.5 mM sample of 15N-labelled p53BD4 was 
recorded. 400 l of a 0.52 mM unlabelled p53CD was added, producing a final 
p53CD concentration of 0.4 mM and a final p53BD4 concentration of 0.2 mM, after 
which the 15N-HSQC spectrum of p53BD4 was recorded again. An overlay of the two 
spectra is shown in Figure 3.21. As before, there are no significant differences 
between the two spectra. In particular there is no clear evidence of new, more 
dispersed, peaks which might indicate the presence of folded molecules of p53BD4. 
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Figure 3.20 15N-HSQC of 15N-labelled p53CD, with (red) and without (black) 
unlabelled p53BD4 No significant chemical shift perturbations of the 15N-HSQC 
spectrum of 15N-labelled p53CD were observed following addition of unlabelled 
p53BD4, suggesting that the domain does not undergo major conformational 
changes upon p53BD4 binding. The spectra were acquired at 25°C on a 600 MHz 
spectrometer. A spectrum was first recorded for p53CD without p53BD4 added 
(black). 300 µM of 15N-labelled p53CD was mixed with 400 µM unlabelled p53BD4 
at a molar ratio of 1:1.3 and data recorded for 18 hours (red spectrum).  
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Figure 3.21 15N-HSQC of 15N-labelled p53BD4 with p53CD added (red) and without 
unlabelled p53CD added (black) No significant chemical shift perturbations were 
observed for 15N-labelled p53BD4 upon addition of unlabelled p53CD, suggesting that the 
domain does not undergo major conformational changes upon p53CD binding. The 
spectra were acquired at 25°C on a 600 MHz spectrometer. A spectrum was first 
recorded for 15N-labelled p53BD4 without p53CD added (black). 200 µM of 15N-labelled 
p53 BD4 was mixed with 400 µM unlabelled p53CD at a molar ratio of 1:2 and data 
recorded (red spectrum).  
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3.6 Discussion 
Various fragments of the p53 binding domain of RBBP6 were successfully cloned 
into a pGEX-6P-2 expression vector and expressed in a bacterial system. GST pull-
down assays identified p53BDFL as well as p53BD4 (residues 1422-1668 of RBBP6) 
as interacting with the core DNA binding domain of p53. These results were verified 
by co-immunoprecipitation of bacterially expressed p53BD4 by full length p53 
expressed endogenously in a HEK293T lysate.  Surprisingly p53BD1, which spans 
the RBBP6 region previously defined as the p53 interaction segment by Gao and 
Scott, failed to precipitate p53CD. The R273H mutant of p53, which is located in the 
core DNA binding domain, was generated using site-directed mutagenesis PCR and 
expressed in E. coli. GST pull-down assays were repeated with the mutant protein 
and p53BD4 but the mutation failed to abolish the interaction between p53CD and 
p53BD4, contrary to what was expected from the report by Simons and co-workers. 
Although p53BD4 was predicted to be unfolded, a sufficient quantity of soluble 
protein was produced for NMR analysis. NMR analysis confirmed that the protein is 
unfolded under the buffer conditions used for the NMR experiments.  
 
P53CD was successfully expressed as a 6xHis-MBP fusion protein and purified 
using a combination of immobilised metal affinity chromatography and heparin 
affinity chromatography. The final concentrations of p53CD ranged from 0.2-0.4 mM, 
which are near an upper limit of the reported solubility [125]. Purified p53CD 
preparations were characterised by mass spectrometry and NMR. The 15N-HSQC 
spectrum of the purified p53CD indicated that the domain is well folded. The 15N-
HSQC spectrum showed high similarity to a previously published, assigned spectrum 
of the domain. Thus no attempt was made to re-assign the spectrum. 
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Although the results presented here localise the interaction between RBBP6 and p53 
to the p53BD4 and the p53 core domain respectively, due to the lack of chemical 
shift perturbations we were unable to characterise the interaction from a structural 
point of view. In particular, we were unable to identify individual amino acids involved 
in the interaction and were therefore unable to generate mutants for use in functional 
studies. Several possibilities exist to explain the lack of chemical shift perturbations 
seen with the 15N-HSQC experiments. Firstly, it is possible that the interaction 
involves side chain-side chain contacts that are not detected using 15N-HSQC-based 
experiments. A second possibility is that the interaction is sufficiently weak that too 
little of the complex was present to be observable in our NMR spectra. A third 
explanation is that the combined size of the complex 25 kDa + 29 kDa = 54 kDa, 
resulted in line broadening and a corresponding decrease in sensitivity. In our 
opinion a combination of the second and third explanations most probably accounts 
for the failure to observe the interaction using NMR. 
 
The failure of the R273H mutation to abolish the interaction is possibly due to small 
differences between the interface in mouse and human. Future work will include 
other mutations, most notably the R273C mutant, since this may mimic the published 
effect more effectively than the R273H mutant we chose to use. 
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Chapter 4: Ubiquitination of Y-box binding protein 1 by RBBP6 
4.1 Introduction 
Our group has previously shown that RBBP6 interacts with the C-terminus of Y-box 
Binding Protein 1 (YB-1) through its RING finger domain [70]. It was furthermore 
reported that overexpression of both RBBP6 and the isolated RING finger domain 
led to decreasing intracellular levels of YB-1 in a proteasome-dependent manner, 
indicating that YB-1 was being ubiquitinated by RBBP6 and degraded by the 
proteasome.  
 
To further investigate the ubiquitination of YB-1 by RBBP6, we set out to reproduce 
the reaction in vitro using purified bacterially-expressed proteins. Because of the 
large size and poor solubility of full length RBBP6, we decided to express a smaller 
fragment denoted R3, consisting of the first 335 amino acids and including only the 
DWNN domain, the zinc finger and RING finger domains (see Figures 1.1 and 3.2). 
We hypothesised that since it included the RING finger domain and corresponded to 
the primitive form of RBBP6 found in lower eukaryotes, R3 was likely to retain the 
ubiquitination activity of full length RBBP6. The I261A mutation in the RING finger 
domain of RBBP6 corresponds to the I26A mutation in BRCA1 which has been 
shown to disrupt the binding of the ubiquitin-conjugated E2 to the RING finger 
domain of BRCA1 [126]. The I261A mutant form of R3 was therefore produced to act 
as a negative control for the ubiquitination of YB-1 by R3. 
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Samples of R3, R3-I261A, YB-1 and HA-ubiquitin were produced in bacteria and 
used to investigate the ubiquitination of YB-1 by R3 in vitro. A panel of E2s was 
obtained commercially and used to investigate the E2 preference of R3. 
 
4.2 Cloning, recombinant expression and purification of GST-R3, GST-
YB-1 and HA-ubiquitin 
4.2.1 Cloning of R3 and YB-1 fragments into pGEX-6P-2 
Plasmids harbouring wild type and mutant (I261A) DNA sequences for RBBP61-335 
were synthesised by GenScript (GenScript Inc., New Jersey, USA) and supplied in 
the pUC57 vector. The sequences are codon-optimised for E. coli and included 
BamHI and XhoI restriction sites for subcloning the fragments into pGEX-6P-2, as 
well as C-terminal 6xHis fusion tags to facilitate purification of the expressed proteins 
and to reduce C-terminal degradation by allowing selection of full length proteins. 
The pUC57-R3-6xHis plasmids were digested with BamHI and XhoI and the R3-
6xHis fragments excised from an agarose gel (Figure 4.1(A)), before being cloned 
into pGEX-6P-2. Plasmid DNA was isolated and digested with BamHI and XhoI to 
release R3-6xHis inserts as shown in Figure 4.1(B).  
 
Near full-length human YB-1, cloned into pGEX-4T1, was obtained from Prof Antony 
Braithwaite of the University of Sydney, Australia. The pGEX-4T1-YB-1 construct 
lacked the coding sequence for the six C-terminal residues of YB-1 and, in addition, 
contained a frame-shift mutation causing read-through past the stop codon. 
Fortunately the construct had a unique EcoRI restriction site immediately 5’ to the 
frameshift mutation. The errors were corrected by a pair of complementary  
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pUC57 
R3His 
M     1     2    3 
1031 bp 
1500 bp 
1031 bp 
1500 bp 
R3His 
Figure 4.1 Cloning of R3-wt and R3-I261A into pGEX-6P-2 (A) Restriction digests of pUC57-
R3wt and pUC57-R3-I261A with BamHI and XhoI. Lane 1 shows digested pUC57-R3-wt 
plasmid DNA, while lanes 2 and 3 show pUC57-R3-wt and pUC57-R3-I261A DNA respectively, 
following removal of the R3-wt and R3-I261A-containing gel slices. (B) Restriction digests of 
pGEX-6P-2-R3-wt and pGEX-6P-2-R3-I261A with BamHI and XhoI. Lane 1-3 shows pGEX-6P-
2-R3-wt digested with BamHI, while lanes 4 and 5 show digested pGEX-6P-2- R3-I261A. All 
lanes show release of inserts of the appropriate size. 
M  1  2  3   4   5 
A 
B 
pGEX-6P-2 
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oligonucleotides which when annealed, produced a double stranded DNA sequence 
coding for the missing residues, flanked by “sticky ended” EcoRI and XhoI restriction 
sites (see Table 5.1).  
                                         
Oligonucleotide 
name 
Sequence 
YB-1A 5’-AAT TCG TCC GCT CCC GAG GCT GAG CAG GGC GGG 
GCT GAG TAA TGA C-3’ 
YB-1B 5’-TC GAG TCA TTA CTC AGC CCC GCC CTG CTC AGC CTC 
GGG AGC GGA CG-3’ 
 
 
The oligonucleotides were annealed as described in Section 2.6.4 and ligated into 
pGEX-4T1-YB-1 which had been previously digested with EcoRI and XhoI. Following 
transformation and plasmid isolation, the full-length YB-1 fragment was subcloned 
into pGEX-6P-2 which had been digested with BamHI and XhoI. R3 and YB-1 
containing constructs were verified by direct DNA sequencing.  
 
4.2.2 Expression and purification of R3, YB-1 and HA-ubiquitin 
Both GST-R3-wt and GST-R3-I261A fusion proteins were found to express solubly 
and at reasonably high levels in E. coli. Fusion proteins were purified out of cell 
lysates using glutathione affinity chromatography (see Figures 4.2(A) and (B)). The 
GST fusion partner was removed using 3C protease and the R3 proteins were 
purified by size exclusion chromatography (data not shown). 
 
 
Table 5.1 YB-1 linker oligonucleotides 
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Figure 4.2 Purification of GST-R3-wt (A) and GST-R3-I261A (B) Clarified 
lysate (lane 1) was passed over a glutathione agarose column and the flow 
through (lane 2) collected. The column was washed extensively with Wash 
Buffer (lane 3) before elution of the bound fusion protein with 20 mM 
reduced glutathione. Lanes 4 and 5 shows a band of approximately 72 kDa, 
corresponding to the expected size of the GST-R3 fusion proteins. The 
respective fusion proteins containing fractions were pooled and cleaved with 
3C protease. 
72 kDa  GST-R3-I261A 
M     1          2       3        4        5            
M    1          2        3      4       5            
GST-R3-wt 72 kDa 
B 
A 
 
 
 
 
93 
 
GST-tagged YB-1 was expressed and purified using GST affinity chromatography, 
but produced no clear band of the expected size of 50 kDa on SDS-PAGE. YB-1 has 
been reported to form high molecular weight oligomers by Gaudreault and co-
workers [127], so SDS-PAGE gels were immunoblotted with anti-YB-1 antibodies 
against the C-terminus of YB-1 (kindly provided by Prof Antony Braithwaite, 
University of Sydney, Australia) [79, 80]. The intense smear in Figure 4.3(A) shows 
that large amounts of YB-1 are present and confirms that YB-1 is forming high 
molecular weight oligomers.   
 
Gaudreault and co-workers further reported that the oligomers could be eliminated 
by addition of ATP [127]. Although the precise mechanism remains unclear, YB-1 
homodimerization has been shown by Izumi and co-workers to be mediated by the 
C-terminal tail of YB-1 [49].  When ATP was added to an YB-1 sample it produced a 
single band on SDS-PAGE of the expected size of 50 kDa (Figure 4.3(B)).                
               
HA-ubiquitin was expressed in E. coli Rosetta 2 (DE3) cells, using a construct kindly 
provided by Prof Rachel Klevit of the University of Washington, Seattle, USA. Since 
the target protein contained no affinity tag, an alternative strategy was used to purify 
it based on acetic acid precipitation and cation exchange, as described in Section 
2.11.4.5. The final purified protein can be seen in lanes 5-8 of Figure 4.4. 
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Figure 4.3 Immunodetection of YB-1 shows it forms oligomers Purified 
bacterially expressed YB-1 was detected using a rabbit polyclonal anti-YB-1 
antibody. Lanes 1 and 2, containing 1 g of purified YB-1 each, in (A) 
indicates that YB-1 forms high molecular weight oligomers in solution, in 
addition to being highly susceptible to proteolytic cleavage. YB-1 oligomer 
formation was reversed by incubation with 4 mM ATP, as seen in (B). 
       1      2 
Purified YB-1  
Purified YB-1  
Purified YB-1 after treatment with 4 mM ATP 
50 kDa  
 
Untreated purified YB-1 
B A 
40 kDa  
40 kDa  35 kDa  
35 kDa  
50 kDa  
72 kDa  72 kDa  
96 kDa  
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Figure 4.4 Purification of HA-ubiquitin Bacterial proteins were precipitated with 
glacial acetic acid and the soluble fraction, containing HA-ubiquitin dialysed against 
sodium acetate, pH 4.5. Precipitated proteins were pelleted and the soluble fraction 
loaded on a POROSR S20 column pre-equilibrated with sodium acetate, pH 4.5. 
Unbound proteins were washed off the column with sodium acetate. Bound proteins 
were eluted off the column with PBS containing increasing concentrations of NaCl. 
HA-ubiquitin containing fractions (lanes 6-8) were pooled, dialysed against PBS and 
concentrated to 1.5 ml. Purified HA-ubiquitin was divided in 500 μl aliquots, 10 % 
glycerol added and the protein stored at -20 °C. 
HA-ubiquitin 
M      1        2      3     4       5       6       7       8       9 
14 kDa  
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4.3 Ubiquitination assays 
4.3.1 Ubiquitination of YB-1 by R3-wt 
In vitro ubiquitination assays were performed as described in Section 2.11.11. 
Initially, assays were conducted with purified R3-wt and YB-1 as the E3 and 
substrate, respectively. The purified proteins were mixed with HA-ubiquitin, 
commercial E1, Mg-ATP and a number of different enzymes E2s (UbcH2, UbcH3, 
UbcH5C, UbcH7, UbcH8 and UbcH10 respectively) (Boston Biochem Incorporated, 
Cambridge, Massachusetts, USA). These assays failed to produce any ubiquitinated 
YB-1 products when probed with either anti-YB-1 or anti-HA antibodies (data not 
shown).  
 
However when HEK293T cell lysate was added to the reaction, YB-1 was found to 
be degraded in an R3-dependent manner. Figure 4.5(A) shows YB-1 detected using 
the rabbit polyclonal antibody against the C-terminus of YB-1 supplied by Prof 
Braithwaite. Lane 1 shows full length YB-1 (50 kDa), as well as degradation products 
at approximately 32 kDa and 23 kDa respectively, in the presence of cell lysate, E1, 
E2 (UbcH3) and ubiquitin. On addition of R3 YB-1 dramatically disappears (lane 2).  
 
However YB-1 can be completely rescued by addition of the proteasome inhibitor 
MG132 (lane 3), indicating that the disappearance of YB-1 is due to degradation in 
the proteasome. Consistent results were obtained using HeLa cell lysate, as shown 
in Figure 4.5(B). 
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A 
40 kDa 
30 kDa 
20 kDa 
50 kDa 
60 kDa 
YB-1  
*  
*  
**  
M           1      2      3 
HEK293T lysate          
YB-1 
R3-wt 
MG312                                 
+      +      +  
+      +      +      
-       +      +      
-    -       +         
B 
50 kDa 
40 kDa 
30 kDa 
60 kDa 
 YB-1  
*  
M    1     2      3 
HeLa lysate 
YB-1  
R3-wt  
MG312 
+    +      +  
+    +      +       
-    +       +       
-     -       +          
Figure 4.5 R3 induces proteasomal degradation of YB-1 in vitro Purified YB-1, 
R3-wt and HA-ubiquitin was incubated with either a HEK293T (A) or HeLa cell lysate 
(B). In the absence of R3-wt (lane 1 in A and B) there was no observable degradation 
of YB-1. Addition of R3-wt to the reaction resulted in the degradation of YB-1 as seen 
in lane 2 in (A) and (B), indicating that R3-wt is required for YB-1 ubiquitination. 
Inhibition of the proteasome by MG132 stabilises YB-1 as seen in lane 3. YB-1 was 
immunodetected with a rabbit polyclonal antibody against a C-terminal epitope of YB-
1. Asterisks denote YB-1 degradation products. These degradation products are not 
the result of proteasomal cleavage as they appear in lane 1, where no R3 is present. 
Lane 3 in A possibly shows a YB-1 degradation product with one ubiquitin moiety 
attached to it, indicated by the double asterisks (**). 
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4.3.2 Ubiquitination of YB-1 by R3-I261A    
The previous results suggest that wild-type R3 is required, but not sufficient, for 
ubiquitination and proteasomal degradation of YB-1 in vitro. To probe the presumed 
ubiquitination, a mutant form of R3 (R3-I261A) was used which is known to interfere 
with the binding of the E2 UbcH5 to the E3 BRCA1 [126]. The equivalent mutation 
(I383A) in c-Cbl interferes with the binding of the E2 UbcH7 to c-Cbl [104]. 
Surprisingly I261A was not able to block the degradation of YB-1, as shown in lane 5 
of Figure 4.6. Although these results were only obtained using the E2 UbcH2, they 
begin to suggest that while RBBP6 is required for ubiquitination of YB-1, it may not 
interact directly with the E2 and therefore may not be playing the role of E3.  
 
4.3.3 Screening of a selection of E2s active in R3-mediated 
ubiquitination of YB-1 
While it has long been known that E3 ligases confer substrate specificity in the 
ubiquitin-proteasome system [128], it has only recently become clear that E2s 
determines which ubiquitin lysine residue is selected for polyubiquitin chain linkage 
formation [96]. The chain linkage in turn determines the fate of the polyubiquitinated 
substrate; for example, lysine48-linked polyubiquitin chains target substrates for 
degradation by the proteasome, while lysine63 linkages  are involved in DNA repair 
pathways [129]. 
 
A commercial panel of E2s was screened to determine which E2s functions most 
effectively with R3-wt in the ubiquitination of YB-1. Degradation reactions were set 
up containing substrate (YB-1), putative E3 (R3), E1, cell lysate and one of the E2s  
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*  
*  
HeLa lysate                
R3-wt                           
R3-I261A                    
UbcH2 (E2)                 
MG132                        
 YB-1  50 kDa  
     1       2        3       4          5           6 
+          +        +         +          +          + 
 -          -         +         +          -            - 
 -          -         -          -           +          +      
 -          +        +         +          +          + 
 -          -          -         +          -           + 
Figure 4.6 R3-I261A does not abolish ubiquitination of YB-1 in vitro Purified 
R3-wt or R3-I261A, UbcH2 and HA-ubiquitin was incubated with HeLa cell lysate 
that was transfected with pCMV-Myc-YB-1. In the absence of R3-wt or mutant R3, 
YB-1 levels are stable as seen in lanes 1 and 2. Addition of R3-wt or R3-I261A 
leads to a decrease in YB-1 levels (lanes 3 and 5), while the presence of the 
proteasome inhibitor MG132 rescues YB-1 from degradation, as seen in lanes 4 
and 6.    
 
 
 
 
100 
 
UbcH3, UbcH6, UbcH8 and UbcH10. UbcH2 had already been shown to produce 
efficient degradation of YB-1 (see Figure 4.6).  
 
Figure 4.7 shows that all of the tested E2s produced some degradation (lanes 2, 4, 6 
and 8) relative to the E2- control (lane 1). In each case the degradation was blocked 
by addition of proteasome inhibitor (lanes 3, 5, 7 and 9). These results are 
preliminary and could not be pursued due to shortage of time and availability of the 
different E2s. However it is not unusual for E3s to cooperate with a number of 
different E2s. This has been shown, for example, by Klevit and Christensen for the 
dimeric RING E3 ligase BRCA1/BARD1 [130]. The authors screened 30 of the 35 
known human E2s for activity with BRCA1/BARD1 and identified 10 different E2s 
that were functional in in vitro ubiquitination reactions with BRCA1/BARD1. The 
authors furthermore demonstrated direct binding of the identified E2s with 
BRCA1/BARD1 using NMR-based binding assays.    
 
4.3.4 RBBP6 RING auto-ubiquitination assay 
A key feature of many E3 ligases is that they contribute to their own destruction by 
catalysing their own ubiquitination [131-133]. To assess whether RBBP6 has intrinsic 
ubiquitin ligase activity, auto-ubiquitination reactions were set up using the 
bacterially-expressed RING domain of RBBP6.   
 
A western blot of the RING domain in the presence of the E2 UbcH3 and ubiquitin is 
shown in Figure 4.8. As previously, HeLa cell lysate was added to assess whether 
the ubiquitinated RING domain is subject to proteasomal degradation. The RING 
domain has a molecular weight of 10.2 kDa. Lane 2 shows multiple ubiquitinated  
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M       1     2      3     4       5     6       7      8       9   
     +       +      +       +      +      +      +       +      +  
     +       +      +       +      +      +      +       +      + 
      -       3      3       6      6      8       8     10    10 
      -       -       +        -      +      -       +       -       +                
HeLa lysate                           
R3wt            
E2                
MG132             
20 kDa  
30 kDa  
40 kDa  
50 kDa  
60 kDa  
Figure 4.7 Screening of a selection of E2s active in R3-mediated YB-1 ubiquitination 
Bacterially expressed R3-wt, YB-1 and HA-ubiquitin were incubated overnight with a 
selection of E2 enzymes at 37 °C. Proteins were western blotted and YB-1 detected with a 
rabbit polyclonal antibody against a C-terminally located YB-1 epitope. When comparing E2-
containing reactions without and without added proteasome inhibitor MG132, it is clear that 
all the tested E2s are to some extend active in YB-1 degradation (see lanes 2, 4, 6 and 8). In 
each case YB-1 is rescued from degradation by addition of MG132 (lanes 3, 5, 7 and 9). 
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Figure 4.8 Auto-ubiquitination of the RBBP6 RING domain using a HeLa cell 
lysate Purified RING domain was incubated with a HeLa lysate in the presence or 
absence of MG132. The domain was detected a rabbit polyclonal antibody 
against the RING domain.  Lane 2 shows bands corresponding to approximately 
22 kDa, 28 kDa and 40 kDa. These bands possibly correspond to different 
numbers of attached ubiquitin moieties; however a mass spectrometric analysis 
will be required in order to confirm this hypothesis. 
RING 
20 kDa 
30 kDa 
40 kDa 
50 kDa 
  M                        1            2 
HeLa lysate                       
RING                                
HA-ubiquitin                    
E2                                     
MG132                              
+            +   
+            + 
+            + 
+            + 
-             + 
RING-Ubn 
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observed (lane 2) which are not present when ubiquitin is omitted (lane 1). These 
results indicate that the isolated RING domain of RBBP6 possesses intrinsic E3 
ligase activity. The RING domain includes 4 lysine residues, all in the C-terminal 
helix; mass spectrometric analysis will be required to determine how many ubiquitin 
moieties are attached to the RING domain, as well as the sites of attachment. 
 
Similar results were obtained in a fully in vitro reaction when the RING domain was 
incubated with HA-ubiquitin in the presence of E1 and E2 enzymes only, as seen in 
Figure 4.9. In the presence of ubiquitin multiple higher molecular weight species are 
observed (lane 2) which are not present when ubiquitin is omitted (lane 1). These 
results indicate that the isolated RING domain of RBBP6 possesses intrinsic E3 
ligase activity. The RING domain includes 4 lysine residues, all in the C-terminal 
helix; mass spectrometric analysis will be required to determine how many ubiquitin 
moieties are attached to the RING domain, as well as the sites of attachment. 
 
4.4 Discussion 
A large number of studies have implicated YB-1 in tumourigenesis, tumour cell 
progression and poor patient outcome [38-42], making it an attractive target for anti-
cancer therapy. Pathways which degrade or down-regulate YB-1 may therefore 
provide ways of controlling its tumourigenic effects. The F-box protein FBX33 was 
previously shown to recruit YB-1 and cause its ubiquitination by a SCF-E3 ligase 
complex, resulting in degradation in the proteasome [67]. 
 
More recently, overexpression of RBBP6 in HEK293 cells was shown to down-
regulate YB-1 in a proteasome-dependent manner [70]. Since YB-1 was also shown  
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RING 
RING-Ubn 
RING                       
HA-ubiquitin      
E1                      
E2                      
Mg-ATP             
60 kDa 
50 kDa 
40 kDa 
30 kDa 
20 kDa 
1       2 
Figure 4.9 In vitro auto-ubiquitination of the RBBP6 RING 
domain Purified, bacterially expressed RBBP6 RING domain was 
incubated with (lane 2) and without (HA-ubiquitin) in the presence 
of E1 and E2 enzymes at 37 °C. Following electrophoresis and 
transfer to a PVDF membrane, the RING domain was detected 
with a rabbit polyclonal antibody raised against bacterially 
expressed RING domain. Addition of HA-ubiquitin leads to the 
formation of poly-ubiquitinated RING species, seen in lane 2. No 
ubiquitination of the RING domain is seen in the absence of HA-
ubiquitin (lane 1). The presence of poly-ubiquitinated forms of the 
RING domain seen in lane 1 clearly indicates that the domain 
possess intrinsic E3 ligase activity. 
+         +       
-          + 
+         + 
+         + 
+         + 
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to interact directly with the RING finger domain of RBBP6, the conclusion was drawn 
that RBBP6 acts as an E3 ligase, directly ubiquitinating YB-1.      
 
The results presented here suggest that although RBBP6 promotes ubiquitination of 
YB-1, it is not sufficient. In fully in vitro ubiquitination assays a truncated form of the 
protein, containing only the DWNN domain, the zinc finger and the RING finger 
domain, was unable to ubiquitinate YB-1. However, in the presence of HeLa or 
HEK293T cell lysates R3 catalyzed degradation of YB-1 in a proteasome-dependent 
manner, suggesting that R3 promotes ubiquitination of YB-1. 
 
Ubiquitination of YB-1 was not convincingly demonstrated, although preliminary 
evidence of ubiquitination can be seen in Figure 4.6(A) (YB-1** in lane 3). Addition of 
ubiquitin aldehyde, which inhibits de-ubiquitination, may yield more convincing 
results. The use of an anti-HA antibody may also be more effective in detecting HA-
ubiquitin-modified YB-1. 
 
The above results suggest that, in addition to proteasomes, the cell lysates contains 
an additional factor (or factors) which assist RBBP6 in ubiquitinating YB-1. One 
possibility is that RBBP6 acts as a scaffold onto which the “real” E3 and substrate 
bind. A similar model has been advanced for the role of RBBP6 in the ubiquitination 
of p53 by MDM2 [8]. This model is supported by our finding that, although the RING 
domain appears to be essential for ubiquitination of YB-1, a mutation known to inhibit 
binding of the E2 to its cognate E3 does not inhibit the ubiquitination of YB-1, 
suggesting that RBBP6 may not be playing the role of the E3. 
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A preliminary screen of a number of different E2s suggested that more than one may 
be active with R3. A more careful study will be required before a clear picture of the 
E2 specificity will begin to emerge. 
 
Our data suggest that, in common with many E3s, RBBP6 is able to ubiquitinate 
itself. Higher molecular weight species were seen in the presence of ubiquitin, which 
disappeared when ubiquitin was omitted. In the presence of cell lysates these bands 
were present in the presence of proteasome inhibitor, but disappeared when the 
inhibitor was omitted, suggesting that they are degraded by the proteasome. These 
studies were carried out using antibodies against the RING domain; more convincing 
results are likely to be obtained using antibodies recognising HA-ubiquitin. It is 
possible that auto-ubiquitination is responsible for maintaining the very low resting 
levels of RBBP6 which have made detection of endogenous RBBP6 very 
challenging. It would therefore be of interest to use mass spectrometry to identify the 
precise sites of auto-ubiquitination so that these may be mutated in order to produce 
mutant forms for in vivo studies which are not subject to degradation. 
 
Also of interest would be to use mass spectrometry to identify the sites of 
ubiquitination on YB-1, again with the aim of producing ubiquitination-null mutants as 
negative controls in functional studies. However, previous studies have suggested 
that this procedure is not guaranteed of success, because there is often more than 
one possible site of ubiquitination, all which may need to be mutated. 
 
The RING finger domain has been shown to be dimeric at high concentration [134], 
suggesting that the complete protein may also homodimerize. Dimerization has been 
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shown to be necessary for a number of RING finger and U-box-containing proteins, 
including BRCA1 and CHIP [126, 135]. Members of our group have generated 
mutants that abolish the homodimerization of the RING finger. It would be very 
interesting to test whether these mutations have any effect on the ability of RBBP6 to 
catalyze ubiquitination of YB-1. 
 
Finally, perhaps the most interesting challenge lying ahead will be the identification 
of “Factor X”, the factor or factors supplied by the cell lysate. One approach 
envisioned to identify Factor X would be to use GST-R3 to pull-down interacting 
proteins from human cell lysates followed by mass spectrometry to identify these 
proteins. Since Factor X is likely to be another E3 ligase it should be relatively 
straightforward to identify. MDM2 is a possible candidate since it has already been 
shown to cooperate with RBBP6 in ubiquitinating p53 [8]. Due to time constraints this 
avenue of inquiry was not pursued during this study but will be investigated in future 
work.  
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Chapter 5: Conclusions, outputs and future work 
5.1 Main conclusions 
We were able to validate of the interaction between RBBP6 and p53, and localised 
the interaction to the DNA binding domain of p53 and the region 1422-1668 of 
RBBP6. However we were unable to gain any additional structural information or any 
residue-specific information, and were therefore unable to generate null-mutants. We 
were also unable to reproduce a previous report that the R270C mutant of murine 
p53 abolished the interaction with RBBP6. 
 
We were able to confirm the involvement of RBBP6 in the ubiquitination and 
proteasomal degradation of Y-Box Binding Protein 1. The activity against YB-1 
appeared to be very strong, with near total degradation of YB-1 in in vitro assays. 
However RBBP6 was not sufficient for degradation of YB-1, implying that an 
additional factor(s) is supplied by the cell lysate. The identity of this "Factor X" is the 
subject of on-going investigation. 
 
5.2 Additional outcomes 
DNA expression constructs coding for the R3 fragment of RBBP6 and the I261A 
mutant, the core DNA binding domain of p53 and full length YB-1 were generated as 
part of this work. Effective protocols for expression and purification of these, as well 
as for HA-ubiquitin and the E1 enzyme, were developed. The above are all valuable 
resources that will contribute to on-going research on this project. 
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5.4 Publications 
A publication describing the in vitro ubiquitination of YB-1 by RBBP6 and various 
mutants will be submitted for publication during the first half of 2012. We hope to 
report the identity of Factor X as part of this publication. 
 
The R3 construct generated as part of this work is reported in the following 
publication on the structure of the RING finger domain, which was recently accepted 
for publication by the Journal of Biological Chemistry (JBC): 
Solution Structure of the RING Finger-like Domain of Retinoblastoma Binding 
Protein-6 (RBBP6) Suggests it Functions as a U-Box, Mautin A. Kappo, Eiso AB, 
Faqeer Hassem, R. Andrew Atkinson, Andrew Faro, Victor Muleya, Takalani 
Mulaudzi, John O. Poole, Jean M. McKenzie, Moredreck Chibi, Joanna C. Moolman-
Smook, D. Jasper G. Rees and David J. R. Pugh, Journal of Biological Chemistry (in 
press). 
 
 5.5 Future work 
A fully in vitro assay for investigating proteasomal degradation will be established by 
replacing cell lysates with proteasomes purified out of lysates using an antibody 
against the alpha-2 subunit of the proteasome. Additional factors required for the 
ubiquitination of YB-1 will be identified on the basis of their ability to catalyze 
degradation of YB-1 on addition to the reaction. 
 
The ability of R3 and additional factors to ubiquitinate YB-1 in vitro will be 
investigated directly with the addition of ubiquitin aldehyde, which inhibits any de-
ubiquitination activity, and using anti-HA antibodies combined with HA-ubiquitin. 
 
 
 
 
110 
 
The mode of linkage of poly-ubiquitin chains will be investigated using various 
mutant forms of ubiquitin, including Ub-K48R, which will abolish ubiquitination if the 
chains are K48-linked, and Ub-KallR (all lysines replaced by arginines), which will 
reduce all poly-ubiquitin chains to mono-ubiquitin. 
 
The site of attachment of ubiquitin will be investigated using mass spectrometry. 
Following in vitro ubiquitination using Ub-KallR to collapse poly-ubiquitin chains to 
mono-ubiquitin, mono-ubiquitinated YB-1 will be cut out of SDS-PAGE gels, digested 
into peptide fragments using trypsin and the molecular weights of the peptides 
determined using tandem mass spectrometry. Peptides with anomalous molecular 
weights will be analysed for the possible addition of signature amino acids derived 
from the C-terminus of ubiquitin. Identified lysines will then be mutated to arginines 
to generate ubiquitin-null mutants of YB-1 which will be of use in future in vivo 
assays. 
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APPENDIX 
Amino acid sequence of p53CD: 
GAMGSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVD
STPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDD
RNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSF
EVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNN 
 
Serine-5, which is indicated in red, represents the start of p53CD. The first four 
residues originate from the recognition footprint of the Tev protease in the linker 
region between the 6xHis-MBP tag and p53CD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
